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ABSTRACT 
Adoptive Cell Therapy of cancer using T cells is entering mainstream practice after years 
as a research method. Central to the efficacy of this “living therapy” is the function of the 
T cells transferred. T-cells, like other primary tissue cells, undergo differentiation and 
death. Clinical and preclinical data shows that lesser differentiated, less glycolytic, and 
more proliferative-capable cells used for the adoptive transfer yield superior tumor 
responses.  
This introductory section will describe discoveries which elucidate and control T-cell 
differentiation and function for the improvement of adoptive cell therapy. Namely by use 
of inhibition of the PI3k/AKT pathways, and through the discovery of a dual function of 
death and differentiation by the canonical death receptor Fas, which can be parsed apart 
with a mutation from valine to cysteine at the 194 position (C194V), differentiation can be 
withheld while leaving cell proliferation unhindered during T-cell stimulation and 
expansion. The data also reveals that the differentiation signal caused by extracellular Fas 
ligation passes through AKT, revealing both Fas and AKT as points of intervention for 
targeting differentiation along the same pathway.  
From further investigation, this introduction will describe the effect of AKT inhibition on 
T-cell differentiation on a transciptional and metabolic level. The data reveals AKT
inhibition promoted FOXO1 intranuclear organization, which creates a more naive-like
phenotype to the cells, and lower glycolytic status, another phenotype associated with
persistent and long-lived cells. Furthermore, this control of AKT and Fas in T-cells yields
benefits in several modalities of pre-clinical models of adoptive T-cell immunotherapy of
cancer, in both use of a chimeric antigen receptor (CAR) and with use of Tumor
Infiltrating Lymphocytes (TIL). Finally, the real-world applicability of the finding
including the use of AKT inhibition in current approved Adoptive T-cell immunotherapies
will be discussed.
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1 INTRODUCTION 
 
The acquisition of T cell effector function is believed to be a predominantly multifactorial 
process, dependent upon a number of variables working within a context where effector 
function is necessary following TCR ligation and receptor costimulation (Gattinoni and 
Klebanoff, 2012). Elucidation of the differentiation process is important as it would enable 
control of T cell physiology for several purposes, applicable to a wide range of fields 
concerned with tumour biology and immunity alike. For example, control of a cell’s 
differentiation status would allow for the earlier generation of effector cells to fight 
malignancy or infection, withheld effector function could assuage autoimmune 
cytotoxicity or prevent premature exhaustion of cells, and T cells that have become locked 
in a proliferative de-differentiated state may be pushed toward differentiation (Crompton, 
et al. 2014). When conceptualizing T cell differentiation and designing its experimental 
evaluation, it is important to uncouple differentiation and proliferation as two distinct 
processes that often coincide physiologically. 
 
This body of work will describe the efforts to interrogate and control the differentiation 
process with methods which keep the proliferative abilities of the cell intact. As clinical 
data suggests that lesser-differentiated cells are more efficacious for tumour 
immunotherapy in addition to the aforementioned advantages of differentiation control 
(Gattinoni and Klebanoff, 2012), it is important to evaluate the therapeutic benefit in 
adoptive cell tumor therapy models of T cells with differentiation withheld through 
antibody-based and pharmacological means.  
  
To begin, the ability of AKT inhibition to withhold differentiation of T cells during IL-
2/TCR/CD28 stimulation was hypothesized and tested. This led to the observation of the 
uncoupling of the differentiation and proliferative processes of the cells by AKT inhibition 
(Leonardi and Crompton 2012, Crompton et al., 2015). Then the effectiveness of AKT 
inhibition in preventing differentiation and in allowing proliferation of stimulated human 
Tumor Infiltrating Lymphocytes (TILs) derived from resected melanomas was tested 
leading to the observation that T cells treated with AKT inhibitor demonstrated an in vitro 
advantage compared to cells that were untreated with AKT inhibitor (Crompton et al., 
2015). The same study also investigated if withholding differentiation via AKT inhibition 
confers an in vivo cytotoxic, effector, and proliferative advantage to the cells in pre-clinical 
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models. These studies then seek to determine the tumor killing ability of cells treated with 
AKT inhibitor by treatment of mice bearing human tumors (xenograft model) and Murine 
tumors (syngeneic model) with adoptive transfer of tumor-specific T cells (Crompton et 
al., 2015, Klebanoff et al., 2017). Taken together the results demonstrated the 
pharmacological modulation of T cell differentiation was a possible option for additional 
TIL and Chimeric Antigen Receptor (CAR) clinical trials for the treatment of metastatic 
Melanoma. 
  
With insight of the signalling mechanism of T cell differentiation through AKT, and the 
observation that antigen-experienced T cells cause accelerated (or precocious) 
differentiation of naïve T cells when exposed to one another, the hypothesis followed that 
there must be a communicable extracellular determinant of differentiation upstream of 
AKT by which Antigen-experienced cells cause the differentiation of their lesser-
differentiated counterparts. To test this hypothesis of a paracrine model of differentiation, a 
method to track subsets of T cells with congenic markers in vitro and in vivo was designed 
in order to observe the phenotypes and function specific subsets had following stimulation 
(Klebanoff et al., 2016). Interrogating this hypothesis yielded experimental evidence 
demonstrating a paracrine, feed-forward mechanism of T-Cell differentiation caused by 
differentiated T cells expressing CD178/FasL (Klebanoff et al., 2016). In further 
development of this discovery, data reveals that T cells may be held in the stem cell 
memory and memory subsets during repeated stimulation by antibody blockade of CD178 
(Klebanoff et al., 2016). Conversely, T cells in less differentiated subsets like naive and 
central memory may be pushed into effector status with exposure to leucine zipper FasL 
(lz-FasL) (Klebanoff et al., 2016). Given the clinical data describing how less-
differentiated clonal populations of T cells are more likely to mediate tumor regression 
following adoptive transfer, the anti-tumor function of T cells treated with CD95L 
blocking antibody during stimulation and culture was tested in a syngeneic murine tumor 
treatment model. Indeed, their lesser-differentiated phenotype yielded a substantial benefit 
(Klebanoff et al., 2016). 
  
Since the data revealed the profound effects of the CD95 and AKT signals on 
differentiation, this mechanistic insight could be applied to fields beyond tumor 
immunotherapy. Autoimmune Lymphocytic Proliferation Syndrome (ALPS) is a condition 
where patient’s T cells have a CD95 signaling deficit due to a loss-of-function mutation, 
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which results in a proclivity for infection and Lymphoma (Cruz AC et al., 2016). Given a 
further understanding of T cell differentiation and as a credit to the discovery, 
collaborators hypothesized and verified the ability of T cells of ALPS patients to signal via 
AKT following CD95 stimulation along with their inability to apoptose (Cruz AC et al., 
2016). Since ALPS patients have mutations in the CD95 domain that affect programmed 
cell death, or apoptosis, of T cells but not the differentiation of T cells, physicians and 
scientists can now appreciate the multifaceted role of CD95 in its cause of ALPS (Cruz et 
al., 2016). Furthermore, tumor immunity is not only dependent upon CD95/CD95L via 
differentiation of T cells, but also that collapse of the tumor stroma in T cell 
immunotherapies of cancer require CD95 stimulation on the stroma of the tumor itself, 
making CD95 a key therapeutic target in the tumor microenvironment (Kerkar et al., 
2013). 
 
This body of work updates the model of T cell differentiation from a nebulous confluence 
of cytokines and contexts, to a well-defined extracellular and intracellular signalling 
pathway that can be controlled for therapeutic benefit. The discovery of this mechanism 
and its ramifications for immunotherapy, infectious disease, and autoimmunity are 
discussed within this work, along with the methodology and experimental results of 
modulation of CD95 and AKT signaling within T cells. 
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2 LITERATURE REVIEW 
2.1 Overview of Adoptive T-cell Therapy of Cancer 
 
For decades, the treatment of cancer patients with T cells recognizing tumor-associated 
antigens had been practiced almost exclusively at the National Cancer Institute, but in the 
late 2000s, academic centers internationally began investigating this experimental, last-
effort approach to fighting metastatic cancer (Radvanyi, 2015). Understandably, the 
therapy is not easily adopted due to the exceptional amount of individually-based steps 
involved which is the case for many such living therapies, but it offers great reward in 
unprecedented long-term response rates (Orlowski et al., 2017, Svane and Verdegall, 
2014). As a barrier of entry to clinicians to employ use of Tumor Infiltrating Lymphocytes 
(TIL), there must be a skilled surgeon to remove a tumor in a patient, the tumor must be 
processed finely in a GMP laboratory, the T cells must be stimulated, cultured, and 
expanded to adequate numbers, the patient must be pre-conditioned by lymphodepleting 
chemotherapy prior to infusion, and post-infusion the patient must be critically monitored 
and treated for any immune-mediated reactions including shock, tumor lysis syndrome, 
cytokine release syndrome, autoimmunity, and pyrexia (Johnson and June, 2017).  
 
An overview of the adoptive T-cell therapy process is shown in figure 1 (Leonardi and 
Modjtahedi, in preparation). Here, two separate paths of Adoptive cell Therapy are shown. 
The path to the left represents scenarios in which T cells must have a transduction in order 
to recognize the target antigen. These cells are taken from the peripheral blood of the 
patient or a matched donor, enriched, then transduced with a CAR or TCR, and stimulated 
in order to expand under varied conditions in order to optimize T cell function (Johnson 
and June, 2017).  The path on the right represents the fragmenting of a tumor to extract the 
Tumor infiltrating lymphocytes, in which the tumor is processed via fragmentation, the T 
cells are stimulated and supported with cytokine and/or molecular agents, and sometimes 
transduced with specific proteins to maximize their tumor-killing efficacy (Hinrichs and 
Rosenberg, 2014). The cells can be divided into clones and selected for therapy based on 
cytotoxic protein release when exposed to the patient’s tumor, or unselected (young TIL) 
and further expanded before being infused in the patient (Hinrichs and Rosenberg, 2014). 
The patient, represented by the figures in the center, is prepared for the infusion of cells by 
a myeloablative chemotherapy regimen of cyclophosphamide, fludarabine, or radiation 
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(Svane and Verdegall, 2014), (Wallen et al., 2009, Rosenberg et al., 2011). Cells are 
occasionally reinfused in cases where further tumor-killing is necessary and probable. 
 
 
 
Figure 1 | Adoptive therapy process overview.  
Two separate paths of Adoptive cell Therapy are shown. The path to the left represents scenarios in 
which T cells must have a transduction in order to recognize the target antigen. These cells are 
taken from the peripheral blood of the patient or a matched donor, enriched, then transduced with a 
CAR or TCR, and stimulated in order to expand under varied conditions in order to optimize T cell 
function.  The path on the right represents the fragmenting of a tumor to extract the Tumor 
infiltrating lymphocytes, in which the tumor is processed via fragmentation, the T cells are 
stimulated and supported with cytokine and/or molecular agents, and sometimes transduced with 
specific proteins to maximize their tumor-killing efficacy. The cells can be selected based on this 
ability or unselected (young TIL) and further expanded before being infused in the patient. The 
patient, represented by the figures in the center, is prepared for the infusion of cells by a 
myeloablative chemotherapy regimen of cyclophosphamide, fludarabine, radiation, or a 
combination of these three. Cytokine support is given following infusion in the form of IL-2 
injection. Cells are occasionally reinfused in cases where further tumor-killing is necessary and 
probable. (Leonardi and Modjtahedi, in preparation) 
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Adoptive immunotherapy of cancer was first used to treat patients in the late 1980s, with 
the use of tumor infiltrating lymphocytes in melanoma lesions resected from metastases 
(Rosenberg et al., 1988, Rosenberg et al., 2008). Figure 2 is a timeline outlining the 
development of tumor immunotherapy for two decades following the first use (Rosenberg 
et al., 2008).  
 
 
Figure 2 | Examples of ACT in patients with cancer EBV, Epstein–Barr virus; PTLD, post-
transplant lymphoproliferative disease; TCR, T-cell receptor; TIL, tumour-infiltrating lymphocytes. 
Figure and Legend used with permission from Nature Reviews Cancer (Rosenberg et al., 2008). 
 
Soon after the first use of TIL for melanoma, treatment of chronic myeloid Leukemia was 
attempted by transferring leukocytes harvested from donors matched in minor 
histocompatibility antigens in 1990 (Rosenberg et al., 2008, Kolb et al., 1990). All three 
patients had remissions of their cancer for 32-91 weeks following treatment (Rosenberg et 
al., 2008, Kolb et al., 1990). Attempts to treat additional histologies included use of donor 
T cell lines targeting Epstein Barr Virus associated Antigens for Hodgkin disease and Post 
Transplant Lymphoproliferative Disorder (PTLD) (Rosenberg et al., 2008, Rooney et al., 
1998, Bollard C, et al., 2004). However, the T-cell receptors (TCRs) on these cells were 
naturally occurring. It was not until 2006 that lymphocytes were genetically engineered to 
express two distinct types of tumor antigen detecting proteins- one, a TCR much like those 
found endogenously on T cells, (Rosenberg et al., 2008, Morgan et al., 2006) and two, a 
chimeric antigen receptor (CAR), which is a protein chimera with an antibody-like 
extracellular domain and an intracellular T-cell CD3 signaling domain (Johnson and June, 
2017, Dunn et al., 2004). More specifically, in the composition of a CAR, the heavy and 
light chains are linked by a Single-chain variable fragment and the same intracellular 
signalling domain as a T-cell, CD3, is used (Johnson and June, 2017).  Figure 3 compares 
the CAR and the TCR (Johnson and June, 2017). 
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Figure 3 | T-cell receptor (TCR) and chimeric antigen receptor (CAR) structure. T-cell 
receptors are composed of two separate proteins, the alpha (α) and beta (β) chains. TCR antigen-
binding sites are located in the membrane-distal variable regions, which are attached to the 
membrane-proximal constant region. CARs are composed of a membrane-distal single-chain 
variable region (scFv) made of the variable heavy and light chains joined by a linker molecule. 
Upon encountering cognate antigen, T-cell activation by both TCR and CAR occurs through 
intracellular TCR zeta (ζ) signaling. Figure and legend used with permission from Cell Research 
(Johnson and June, 2017). 
 
 
2.2 Cancer Immunogenicity and the Tumor Microenvironment 
 
The tumor microenvironment is a major factor contributing to the success of an adoptive 
cell transfer. Immune surveillance of cells exists in the steady state of an organism (Dunn 
et al., 2004). The adaptive immune system is capable of recognizing aberrant cellular 
facets such as genetic instability, in which cells proliferate into daughter cells which harbor 
heterogenous tumor-associated or tumor-specific cell surface markers (Dunn et al., 2004, 
Vinay et al., 2015). The genetic instability that creates markers for T cells to recognize can 
also create features which allow the tumor to evade the immune system (Dunn et al., 2004, 
Vinay et al., 2015). The quality of a tumor by virtue of this instability, to gain features 
which stimulate the immune response is known as immunogenicity. As stated earlier, 
tumors often contain T-cells (TILs) which recognize antigens expressed by the cancer. In 
these cases, the tumor is able to proliferate and evade destruction through several means, 
which constitute the concept known as immune evasion (Vinay et al., 2015). In tumor, 
myeloid cells which are responsible for antigen presentation may become dysfunctional 
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and no longer present antigen in a context which indicates need for destruction (Kerkar et 
al., 2011). In cases where the immune system surveils tissues and tumor, cooperation is 
necessary between Cytotoxic lymphocytes and myeloid-derived stromal cells, 
macrophages, and dendritic cells in which antigen is taken up and presented to CD8+ T 
cells in order to license the T cell to destroy tumor stroma in a mechanism known as cross-
presentation (Kerkar et al., 2011). In a tumor’s steady state, immune tolerance is induced 
and maintained by resident T-regulatory cells (Tregs) which are even more adept at 
quelling cytotoxic responses to tumor antigens than peripheral-blood resident Tregs 
(Chaudhary et al., 2016). 
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2.3 Factors Contributing to Successful Adoptive Immunotherapy of 
Cancer 
 
In clinical and pre-clinical trials, decades of studies of ACT have been undertaken in order 
to discover and use the conditions that confer the best outcomes. With the observation of 
human clinical trials, correlates of successful tumor treatment can be uncovered. In 
addition to striking markers of a successful treatment like vitiligo one such correlate to 
success is the use of a lymphodepleting regimen prior to the infusion of the cancer-
targeting T-cells (Rosenberg, et al., 2008). This is expected to be due to the 
aforementioned immune-suppressive environment which includes “cytokine sinks” 
(Gattinoni et al., 2005). These “cytokine sinks” are other immune cells such as T- 
regulatory cells which soak up the stimulatory cytokines like IL-2 and proliferate in the 
stead of the adoptively transferred cells (Gattinoni et al., 2005). In one clinical trial, the 
highest dose of total body irradiation given as a preparatory regimen at 1200cGy, 
correlated with the highest Objective Response Rate (ORR), presumably due to the 
ablation of “cytokine sinks” (Dudley et al., 2008). The dataset in this paper also revealed 
that higher levels of lymphodepletion also yielded higher concentrations of the 
lymphoproliferative cytokines IL-7 and IL-15 in serum, which are the cytokines that 
adoptively transferred T cells compete for with the cytokine sinks (Dudley et al., 2008). In 
further analysis of T cell phenotypic correlates to tumor response, the identification of 
factors deemed beneficial by virtue of more youthful T cells was made, as indicated by 
longer telomeres, higher expression of CD27 (which is a TNF family receptor necessary 
for the maintenance of memory) (Hendriks et al., 2000), and longer in vivo persistence 
(Rosenberg et al., 2011).  
 
This data reaffirmed the necessity of the efforts to elucidate the mechanisms of T-cell 
persistence, especially for the use of adoptive cell therapies. Additionally, many pre-
clinical models have shown that the differentiation status of cells correlates with their in 
vivo efficacy in adoptive immunotherapy of cancer. In the following section, the 
differentiation of T-cells will be discussed from naive to effector with emphasis on the 
application to adoptive cell therapies. 
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2.4 T-cell Differentiation 
 
Like many other tissues in the body including the central nervous system, the intestines, 
skin, lungs, and heart, lymphocytes also have stem cells which are marked by the ability to 
self-renew and divide asymmetrically (Klebanoff and Gattinoni, 2012). After division, the 
daughter cells may undergo differentiation into subsets which are prompted contextually 
by antigen presenting cells (APCs) (Klebanoff and Gattinoni, 2012). These subsets follow 
a progressive model of differentiation from the Naive state, in which the cell has not been 
stimulated to a final state of effector, as evidenced by the epigenetic landscape and ability 
of the cells to self-renew in transplant experiments (Crompton et al. 2016). Figure 4 details 
the differentiation states of a T-cell and the markers associated with each stage along the 
lifespan of a T cell (Klebanoff and Gattinoni, 2012). 
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Figure 4 | A model of progressive T cell differentiation. During an immune response, naive T 
(TN) cells are primed by antigen-presenting cells (APCs). Depending on the strength and quality of 
stimulatory signals, proliferating T cells progress along a differentiation pathway that culminates in 
the generation of terminally differentiated short-lived effector T (TEFF) cells. When antigenic and 
inflammatory stimuli cease, primed T cells become quiescent and enter into the memory stem cell 
(TSCM), central memory (TCM) cell or effector memory (TEM) cell pools depending on the signal 
strength received. The phenotypic attributes, expression levels of key transcription factors and 
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Figure 4… microRNAs (miRNAs), and the functional properties of naive and memory T cell 
subsets are illustrated as not expressed (–), low expression (+), intermediate expression (++) and 
high expression (+++). EOMES, eomesodermin; FOXP1, Forkhead box P1; ID, inhibitor of DNA-
binding; IFNγ, interferon-γ; IL-2, interleukin-2; KLF, Kruppel-like factor; KLRG1, killer cell 
lectin-like receptor subfamily G, member 1; LEF1, lymphoid enhancer-binding factor 1; ND, not 
determined; PRDM1, PR domain-containing 1 with ZNF domain; TBX21, T-box 21; TCF7, T cell 
factor 7; ZEB2, zinc finger E-box binding homeobox 2. Figure and Legend used with permission 
from Nature Reviews Cancer. (Klebanoff and Gattinoni 2012). 
 
When T cells are adoptively transferred in order to target a tumor, their differentiation state 
must best considered in order to confer the best chances of mediating tumor regression 
(Klebanoff and Gattinoni, 2012). In cases where lesser differentiated cells are used to 
target tumor, there will be greater proliferative capacity and ability to remain in the patient, 
but when a more effector-type population is used, these cells will lack proliferative 
capability and the ability to travel to the lymph nodes and meet with resident antigen 
presenting cells (Klebanoff and Gattinoni, 2012). Figure 5 illustrates the scenarios of 
Adoptive transfer of T cells in different differentiation states for the treatment of tumor 
(Klebanoff and Gattinoni, 2012). 
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Figure 5 | Fighting fire with fire. A | Current T cell based immunotherapies predominantly 
transfer cells with effector memory (TEM)-like phenotypic and functional characteristics. These 
cells have limited self-renewal capacity and are oligopotent. These cells can mediate tumour 
destruction but are handicapped to compete with expanding tumor masses (shown as purple tumour 
cells) that are sustained by the activity of self-renewing multipotent cancer stem cells (CSCs; 
shown as dark purple tumour cells). B | Future T cell-based immunotherapies might benefit from 
the transfer of T memory stem cells (TSCM) that have enhanced self-renewal and the multipotent 
capacity to form all memory and effector subsets. These properties allow TSCM cells to sustain a 
prolonged immune attack by giving rise to more differentiated, highly lytic effector T (TEFF) and 
TEM cells while maintaining a continuous supply of less differentiated TSCM and central memory 
(TCM) cells that can refresh the pool of cytotoxic T cells over time. In this manner, TSCM cells 
might overtake the last tumour cell, including CSCs, and so cure the host. Figure and legend used 
with permission from Nature Reviews Cancer (Klebanoff and Gattinoni, 2012). 
 
Given the biology of T cells in which they are limited in their ability to proliferate and self-
renew, a reasonable goal in the field of adoptive T cell immunotherapy is control of T cell 
differentiation states in order to withhold premature effector differentiation (Klebanoff and 
Gattinoni, 2012). Control of differentiation is not the only facet of T-cell function, 
metabolism is also an integral component of a cell which would dictate its duration of life 
and persistence (Sukumar et al., 2013). The relation of T cell metabolism to tumor 
immunotherapy will be briefly discussed in the following section. 
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2.5 T cell Metabolism 
 
Metabolic function of cells is tightly correlated with differentiation state and function, with 
naive cells exhibiting fatty acid oxidation and effector cells exhibiting anaerobic glycolysis 
(van der Windt and Pearce, 2012). Notably in 2011, it was found that the AKT signalling 
protein was dispensible for T-cell proliferation, and that AKT inhibition did not hinder  IL-
2 driven glycolytic function (van der Windt and Pearce, 2012, Macintyre et al., 2011). 
Furthermore, the treatment of cells with AKT inhibitor maintained a greater level of 
expression of the memory-associated lymphoid homing marker CD62L compared to 
stimulation without the inhibitor (Macintyre et al., 2011). This data supported the idea that 
differentiation could be uncoupled from proliferation. 
 
 
2.6 Strategies Targeting T-Cell Function to Optimize Adoptive T-Cell 
Therapy of Cancer 
 
In order to maximize the effectiveness of adoptive cell therapy, T cells must be selected 
and fine-tuned for the process, culminating in the maintenance of a T cell population that 
will recognize and kill cells bearing tumor-associated antigen (Klebanoff and Gattinoni, 
2012). The response of a T cell to antigen depends upon a gamut of contexts, and is a 
diverse and complex field of study. Equally complex are the variables to what makes a 
persistent, self-renewing population of anti-cancer T cells. Harnessing particular 
physiological (and if achievable, extra-physiological) states of T cell function by 
manipulation of contextual signalling proteins (both natural and artificial e.g. CARs) and 
substrates to achieve a response to tumor is the predominant goal in adoptive T-Cell 
Immunotherapy.  
 
The current strategies of enhancing the efficacy of Adoptive Tumor Immunotherapy by 
methods believed to augment the tumor killing response of T-cells focus on different 
aspects of cell biology. These include but are not limited to: targeting cell metabolism, 
targeting intracellular cell signaling, checkpoint blockade, altering T-cell fate or 
differentiation, and stimulation the T cells with certain contextual proteins or cytokines. It 
must be noted, however, that any particular strategy of intervention does not exert an effect 
merely on that particular system, but will yield effects detectable on other physiological 
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systems of the T cell (Sukumar et al., 2013). For example, a metabolic strategy of altering 
T cell function may yield an effect seen on the differentiation of the cell, and vice-versa 
(Sukumar et al., 2013). The uncoupling of given physiological systems (e.g. 
differentiation, metabolic, cell-fate, proliferation) can be seen with particular strategies 
(between differentiation and proliferation, for example, as is the case in AKT inhibition), 
but the metabolic and proteomic signatures of the cell remain coherent following 
intervention upon a particular system when measuring the qualities of other systems of the 
cell (Crompton et al., 2015, Sukumar et al., 2013, Sukumar and Gattinoni 2014, Sukumar 
et al., 2016). This section will briefly mention the efforts to better T-cell function for 
adoptive immunotherapy of cancer in order to create context for the efforts described in the 
results. 
 
 
2.6.1  Optimization of Therapies Using a Chimeric Antigen Receptor 
 
CARs have undergone continuous development and optimization, with new iterations 
termed “generations” (Johnson and June 2017). Selected methods to optimize CAR 
therapy are summarized in Table 1 (Leonardi and Modjtahedi, in preparation). Some of 
these methods may include additional costimulation to the first generation CAR (Finney, et 
al., 1998, Weigelin, et al., 2016, Hombach & Abken, 2013, Zhong, et al., 2010), strategies 
to enrich for CAR T-cells prior to infusion which are more likely to function optimally 
(Chang, et al., 2015, ClinicalTrials.gov Identifier: NCT02652910), a method for creating 
CAR-T cells which can be grafted into any person (universal CAR) (Qasim, et al., 2017),  
and methods to construct the CAR’s moieties for optimal targeting and function 
(Watanabe, et al., 2016, Osborn, et al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
16 
 
Method Agent Method of 
Action 
Execution Reference 
CD25+ CARhi Protein Selection FACS Sort Chang, et al., 2015 
CD-28 Costimulatory 
Domain 
(2nd gen CAR) 
Protein Activation/ 
Costimulation 
Viral Construct Finney, et al., 1998. 
4-1BB Costimulatory 
Domain 
(2nd gen CAR) 
Protein Activation/ 
Costimulation 
Viral Construct Weigelin, et al., 2016 
CD-28 & 4-1BB 
Costimulatory 
Domains 
    (3rd gen CAR) 
Protein Activation/ 
Costimulation 
Viral Construct Zhong, et al., 2010 
OX-40 Protein Activation/ 
Costimulation 
Viral Construct Hombach & Abken, 
2013 
Spacer Domain 
Modification 
(CH3 only) 
Protein Controlled 
Tonic 
Signalling 
Viral Construct Watanabe, et al., 
2016. 
CAR Knock-in/TCR 
Knock-out 
Protein Expression CRISPR/Cas9 Osborn, et al., 2016 
AB TCR & CD52 
Deletion 
(Universal CAR T-
Cells) 
Protein Controlled 
Cell 
Activation/Spe
cificity 
TALEN Qasim, et al., 2017 
Memory-enriched 
CAR (meCAR) 
Protein Selection Cell Sort NCT02652910 
 
Table 1 | CAR Optimization. Selected strategies to optimize the function and tumor responses of 
CAR-T therapies which target the T-cell are shown above. (Leonardi and Modjtahedi, in 
preparation) 
 
2.6.2  Strategies Which Target the Metabolism of T Cells 
 
Targeting cellular metabolism in adoptive immunotherapy is a relatively novel approach, 
with  recent studies showing T cells ramp up their energy expenditure and glucose uptake 
from memory to effector, and that the formation of memory and long-lived cells can be 
achieved with Fatty acid oxidation (FAO) instead of glycolysis (Sukumar and Gattinoni, 
2013, Pearce, et al., 2009). On the basis of this insight, further development has shown that 
T cells stimulated in the presence of the glucose uptake inhibitor 2-DG were shown to 
possess enhanced memory and antitumor function (Sukumar et al., 2013). While it could 
be metabolically reprogramming cells from high glucose consumption to low, it could also 
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be selecting out high glucose consuming cells and yielding a less glycolytic population for 
infusion.  
 
2.6.3  Strategies Which Target Contextual Signaling of T Cells 
 
The control of T-cell activity and function can be achieved by use of cytokines. These are 
proteins which are secreted by cells that affect the behavior of other cells, and are used to 
provide contextual signals. For example, the cytokine IL-2 secreted predominantly by 
CD4+ T-cells and causes proliferation and glycolysis of CD8+ T cells and other cells 
which it signals upon (Klebanoff et al., 2004). This section will briefly describe some of 
the important cytokines for optimizing T cell function in adoptive immunotherapy of 
cancer. 
 
IL-2. During the in vitro T-cell stimulation and expansion phases the viability of the T-
cells depends upon IL-2 much like glucose and serum are necessary for any culture. In 
fact, IL-2 provides a context which causes the T cell to execute a program which includes 
the very consumption of glucose and division of the cell (Boyman and Sprent, 2012). The 
feedback between physiological systems of a cell is evident by virtue of metabolic 
changes, differentiation states, cell proliferation, and gene expression data with the 
addition of IL-2 to a T cell culture. Indeed, increased levels of IL-2 can supplement a weak 
or non-existent CD-28 signal and enact these programmatic changes (Frauwirth et al., 
2002). In addition to its role in the maintenance of T cell culture, IL-2 is given to patients 
following the adoptive transfer of T-cells (Radvanyi, 2015). For the foreseeable future IL-2 
will keep its role as a mainstay in the maintenance of T cell cultures and their preparation 
for Adoptive Cell Transfer. 
 
IL-7. Evidence supports a role of IL-7Rα expression on mouse T cells enabling the 
engraftment of cells transferred in mice in vivo (Johnson et al., 2016). In a depletion 
model, the absence of host-provided IL-7 caused severely impaired persistence compared 
to controls. Furthermore, cells deficient in IL-7Rα expression phenocopied Wild-type 
(WT) T-cells in vitro but had engraftment difficulties similar to the experiment in which 
the host was depleted of IL-7. This suggests that the maintenance of IL-7 signaling 
following the transfer of cells may be a point of intervention, perhaps even to the point of 
achieving supraphysiological levels. 
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IL-12. The Ex-vivo priming of T cell cultures with IL-12 has shown to yield an advantage 
in tumor immunotherapy (Rubinstein et al., 2012), as has its forced expression in T cells 
prepared for transfer, which continually express IL-12 (Kerkar et al., 2013, Lasek and 
Zagozdzon, 2016). Both of these strategies have impressive pre-clinical data with the latter 
having clinical trials, which were halted due to excessive host immune response (Lasek et 
al., 2014). 
 
IL-15. The effects of IL-15 on cell metabolism and differentiation appear promising when 
examined at many points on the path of Adoptive Cell Transfer. The cytokine has shown to 
promote T cell expansion when infused in vivo (Sneller et al., 2011) and memory 
formation when provided in vitro; in pre-clinical models of adoptive cell immunotherapy, 
T cells cultured in IL-15 have shown superior anti-tumor efficacy when compared to IL-2 
(Klebanoff et al., 2004). 
 
IL-33. IL-33 is a potent cytokine which can slow growth of tumors when provided 
exogenously through CD8+ T cell mediated tumor killing (Dominguez et al., 2017). In a 
mouse lymphoma model IL-33 has also been shown to stimulate the growth of human 
Vγ9Vδ2 T cells that can prevent tumor growth after adoptive transfer (Duault et al., 2017). 
 
POTASSIUM MODULATION. Extracellular potassium was shown to withhold effector 
differentiation in the tumor microenvironment- an effect abrogated with the enforced 
expression of Kcna3, a potassium inporter (Eil et al., 2017). This is beneficial for the 
prevention of premature effector function, which would result in poorer tumor treatment. 
 
TNF BLOCKADE. TNFa knockout T-cells adoptively transferred into tumor-bearing 
mice have been shown to yield superior antitumor efficacy compared to controls, believed 
to be due to in part by the effect on tumor neovascularization (Alam, et al., 2015). It has 
been proposed that blockade of TNFR2 may target TNFR2+ tumor-infiltrating Tregs and 
allow for the killing of TNFR2-expressing tumors. 
 
USE OF ALL-TRANS RETINOIC ACID (ATRA). In a pre-clinical model of adoptive 
immunotherapy with CD4+ T cells, groups of mice receiving ATRA survived longer 
compared to controls, due to a significant difference in tumor treatment (Klebanoff et al., 
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2013). Mechanistic inquiry in the study revealed that ATRA treatment forced the 
endogenous Dendritic cell progenitors into a CD11b+CD8α− lineage, which directly 
stimulated the adoptively transferred CD4+ T-cells. In the absence of ATRA, CD4+ T cells 
did not have a sufficient population of CD11b+CD8α− dendritic cells for their stimulation, 
instead a population of CD11b+CD8α+ dendritic cells took hold, meaning in cases where 
CD4+ T cells are adoptively transferred, the lineage of dendritic cells should be controlled 
for optimal responses (Klebanoff et al., 2013). 
 
2.6.4  Strategies Targeting Intracellular Cell Signaling of T Cells 
 
With the use of pharmacological and other agents which target the intracellular machinery 
of cells, cell surface proteins may be bypassed and certain pathways may be targeted. This 
section will briefly detail such methods that have been employed to better T cells for 
adoptive immunotherapy.  
 
In a mouse adoptive immunotherapy model, in vitro stimulation with a PI3K inhibitor 
conditioned T cells to better treat tumor than controls in a mouse adoptive immunotherapy 
model (Eid et al., 2017). The cells were presumed to be superior due to their enhanced 
proliferative ability and memory phenotype. In another study which targeted HIF-
Hydroxylase with the agent dimethyloxalylglycine (DMOG), CD4+ TRP-1 splenocytes 
treated with DMOG during stimulation treated tumor significantly better than controls, 
presumably due to the increased population of cells committing to the Th1 lineage over the 
Treg lineage (Clever et al., 2016). In different terms, treatment of these CD4+ T cells with 
DMOG pushed their differentiation into effector cells which lyse tumor instead of T 
regulatory cells which would dampen the tumor response. This differs from the human 
experience, however, in that splenocytes which are CD4+ Th1 progenitors are not acquired 
for human immunotherapy, but rather T cells which have already differentiated away from 
the T regulatory fate are excised and used as TIL (Gattinoni et al, 2012).  
 
Targeting the mammalian Target of Rapamycin (mTOR) has also been used for 
conditioning T cells during adoptive immunotherapy. Treatment of mice with rapamycin in 
vivo enhanced the effector and memory CD8+ T cell function induced by Ad-Flt3L + Ad-
TK/GCV and increased therapeutic efficacy in an adoptive cell therapy mouse model of 
glioma (Mineharu et al., 2014).  
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2.6.5  Strategies Targeting Checkpoint Inhibitors of T Cells 
 
Since 1975, a wide range of antibodies have been approved which either target tumor 
antigen, or target immune checkpoint inhibitors. These checkpoint inhibitors are proteins 
on the T cell surface that block or inhibit T cell function when they are stimulated (Fig. 6, 
Drew Pardoll, 2012). In one notable example, Pembrolizumab, an antibody targeting 
programmed cell death protein 1 (PD1), was FDA approved for individuals with 
microsatellite instability–high (MSI-H) or mismatch-repair–deficient (dMMR) solid 
tumors (Lemery, et al., 2017). Antibodies against checkpoint inhibitors work by blocking 
the inhibitory interaction between ligands on tumor and receptors on T-cells, and thereby 
allow the T cells to function (Lemery, et al., 2017). Checkpoint inhibitor blocking 
antibodies have been found to enable T cell escape from anergy in vitro as well as in vivo, 
and when used in combination with adoptive cell therapy (Serganova, et al., 2017). This 
section will discuss some of the strategies for improving adoptive immunotherapy by use 
of these checkpoint inhibitors in combination. 
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Figure 6 | Multiple co-stimulatory and inhibitory interactions regulate T cell responses. 
Depicted are various ligand–receptor interactions between T cells and antigen-presenting cells 
(APCs) that regulate the T cell response to antigen (which is mediated by peptide– major 
histocompatibility complex (MHC) molecule complexes that are recognized by the T cell receptor 
(TCR)). These responses can occur at the initiation of T cell responses in lymph nodes (where the 
major APCs are dendritic cells) or in peripheral tissues or tumours (where effector responses are 
regulated). In general, T cells do not respond to these ligand–receptor interactions unless they first 
recognize their cognate antigen through the TCR. Many of the ligands bind to multiple receptors, 
some of which deliver co- stimulatory signals and others deliver inhibitory signals. In general, pairs 
of co-stimulatory–inhibitory receptors that bind the same ligand or ligands — such as CD28 and 
cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) — display distinct kinetics of expression 
with the co-stimulatory receptor expressed on naive and resting T cells, but the inhibitory receptor 
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Figure 6… is commonly upregulated after T cell activation. One important family of membrane 
bound ligands that bind both co-stimulatory and inhibitory receptors is the B7 family. All of the B7 
family members and their known ligands belong to the immunoglobulin superfamily. Many of the 
receptors for more recently identified B7 family members have not yet been identified. Tumour 
necrosis factor (TNF) family members that bind to cognate TNF receptor family molecules 
represent a second family of regulatory ligand–receptor pairs. These receptors predominantly 
deliver co-stimulatory signals when engaged by their cognate ligands. Another major category of 
signals that regulate the activation of T cells comes from soluble cytokines in the 
microenvironment. Communication between T cells and APCs is bidirectional. In some cases, this 
occurs when ligands themselves signal to the APC. In other cases, activated T cells upregulate 
ligands, such as CD40L, that engage cognate receptors on APCs. A2aR, adenosine A2a receptor; 
B7RP1, B7-related protein 1; BTLA, B and T lymphocyte attenuator; GAL9, galectin 9; HVEM, 
herpesvirus entry mediator; ICOS, inducible T cell co-stimulator; IL, interleukin; KIR, killer cell 
immunoglobulin- like receptor; LAG3, lymphocyte activation gene 3: PD1, programmed cell death 
protein 1; PDL, PD1 ligand; TGFβ, transforming growth factor-β; TIM3, T cell membrane protein 
3. Figure and legend used with permission from Nature Reviews Cancer (Drew Pardoll, 2012). 
 
CTLA-4 BLOCKADE. Strategies combining the agents targeting checkpoint inhibitors 
and adoptive immunotherapies have recently emerged to success. In a mouse model of 
ACT where anti-CTLA-4 blocking antibody was infused in vivo alongside the transferred 
cells, the group with the combined therapy exhibited an additive effect (Mahvi, et al., 
2015). There is an ongoing clinical trial using this strategy to target Uveal melanoma at the 
M.D. Anderson Cancer Center (ClinicalTrials.gov Identifier: NCT03068624). 
 
OX40 STIMULATION. Data has shown that OX40 stimulation combined with CD28 
stimulation on CAR-T Cells can reactivate cells residing in peripheral tissues (Hombach & 
Abken, 2013). However, the same group to show this later presented CD28 stimulation 
alone as superior in CAR-transduced Cytokine Induced Killer Cells, given the propensity 
for the combination of CD28 and OX40 to induce Activation Induced Cell Death (AICD) 
(Hombach, Rappl, & Abken, 2013). The cells with combined OX40 signal were shown to 
yield lower antitumor efficacy in vivo. 
 
PD-1/PD-L1 BLOCKADE. Modulation of the PD-1/PD-L1 axis has been widely 
successful as a monotherapy of cancer. With consideration of the mechanism of action and 
the effect of the protein’s inhibition on T-cells, recent studies have shown that in vivo 
antagonization of PD-1/PD-L1 with Adoptive Cell Transfer of CAR-T cells yields better 
antitumor efficacy than cells alone (Serganova, et al., 2017).  
 
4-1BB STIMULATION. A combined approach of tumor therapy of CD137 agonization 
and adoptive immunotherapy seems an enticing option (Weigelin, et al., 2016). A recent 
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clinical trial has shown that agonization of CD137 synergizes with adoptive cell transfer in 
the treatment of cancer in a trial of EBV positive tumors (Eom, et al., 2016).  
 
2.6.6  Strategies Targeting Cell Differentiation 
 
Another strategy for improving adoptive immunotherapy would be to control the 
differentiation state of the T cells directly. By reprogramming the T cells with transcription 
factors associated with the subset desired or into induced pluripotent stem cells (IPSCs), 
younger and more proliferative T cells may be used for adoptive immunotherapy 
(Vizcardo et al., 2018). This technique is more difficult than traditional methods, however, 
in that the efficiency in reprogramming makes for the isolation in relatively few clones 
(Vizcardo et al., 2018). Furthermore, in cases where T cell populations may be selected 
from blood for use of adoptive immunotherapy such as CAR-T or TCR immunotherapies, 
there may be sufficient numbers of lesser-differentiated cells to choose from (Turtle, et al., 
2011, Riddell et al., 2014).  
 
2.7 Current Challenges in the Field 
 
Despite the advances in adoptive immunotherapy two important challenges in the field 
remain: treating the toxicity associated with the T cell response, and using less-
differentiated, more proliferative cells for adoptive transfer. This section will highlight 
these challenges.  
 
Both clinical and pre-clinical data show T cell differentiation state as a major factor in 
treatment efficacy. As described by Klebanoff and Gattinoni, the use of effector 
populations of cells rather than memory will not enable cancer-targeting T-cells to self-
renew and fill the memory compartments (Klebanoff and Gattinoni, 2012). Additionally, 
by use of new technology enabling the tracking of specific populations of T-cell clones 
after infusion, tumor responses have been correlated with lesser-differentiated clones rather 
than their more-differentiated counterparts (Watkins and Miles, 2017). Therefore, in order 
to optimize cell therapy and create more durable responses in patients, controlling the T 
cell differentiation state is a prime goal. This is a challenge however, in that during 
stimulation of T cells in vitro in order to condition them for cytotoxic response to tumor 
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and multiply them in adequate numbers prior to transfer, they differentiate while 
proliferating (Crompton et al., 2014). Therefore there is a need to uncouple differentiation 
from proliferation (Crompton et al., 2014). 
 
While the benefits and capabilities of employing the immune system with adoptive cell 
therapies are numerous, efforts to rectify the associated toxicities must be made. In the 
goal of creating T cells which adequately respond to tumor there is a fine line where 
therapies that may be too strong for the patient begin (Lasek and Zagozdzon, 2016). The 
consideration of how potent an effector response needs to be must be balanced with the 
possibility of toxicity for the patient.  Toxicities associated with adoptive transfer of T cells 
for the treatment of cancer include cytokine release syndrome (CRS), tumor lysis 
syndrome, shock, pyrexia, neuroedema, and lung failure (Neelapu et al., 2018). The 
prevalence of such toxic events is seen as high as 13 percent of the time for CRS and 28 
percent of the time for neurological toxicities (Neelapu et al., 2018).  In the vast majority 
of cases, a critical care center familiar with treating patients who have undergone adoptive 
immunotherapy is able to treat these events, which typically are of limited duration. In fact, 
clinicians familiar with treating leukemia patients with CD19 CARs recognize the severity 
of CRS to correlate with the degree of anti-tumor response (Johnson and June, 2017, 
Davila et al., 2014) Additionally, seemingly safe antigens to target with CARs may prove 
to be hazardous due to the potency of the therapy, which was an issue with a CAR 
recognizing the antigen HER2 (Johnson and June, 2017). In this case, the first patient on 
the trial was infused with with 1 X 1011 T-cells and immediately went into shock, coma, 
and died 5 days later, despite full medical intervention. Expression of HER2 on lung 
epithelium was found to be the cause of the toxicity, even though such toxicity is not seen 
with the HER2 antibody the CAR was designed after (Johnson and June, 2017). Therefore, 
if there is to be wide approval and adoption of cell therapies for cancer, there must be 
further investigation of possible toxicities and their managements must be perfected and 
widely known, or such toxicity abrogated altogether. 
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3 HYPOTHESES TO BE ADDRESSED BY THE WORK  
 
Based on a prior study showing that the presence of antigen experienced cells brings up the 
differentiation baseline of the cell culture in total (Hinrichs et al., 2011) there is evidence 
to hypothesize a paracrine mechanism for T-cell differentiation. Such a mechanism would 
represent a contextual, or extracellular signal. In consideration of this, given the expression 
profile of the Fas receptor in which it is upregulated on stem cell T cells (Gattinoni et al., 
2011) signaling through the Fas receptor is a viable candidate for a paracrine mechanism 
of differentiation. As the efficacy of T cell adoptive immunotherapy of cancer is correlated 
with T cell differentiation, the ability to further control and withhold differentiation of the 
cells may increase treatment efficacy (Klebanoff and Gattinoni, 2012). 
 
To follow the differentiation signal to a point of intracellular signal transduction, based on 
data showing that AKT signaling is not necessary for cell proliferation and that inhibition 
of AKT causes the retention of CD62L, it is reasonable to hypothesize differentiation and 
proliferation have been uncoupled, and that the cell differentiation signal propagates 
through AKT (Macintyre et al., 2011). Given the lesser differentiated phenotype of the 
cells treated with AKT inhibitor, there may be a benefit to cell therapy uses including 
adoptive immunotherapy (Macintyre et al., 2011, Hinrichs et al., 2011). 
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4 AUTHOR’S PUBLISHED DATA AND CONCLUSIONS 
 
This section will highlight key figures from the author’s publications which address the 
hypotheses. All published work represented in the figures is referenced along with the 
specific methods published by the author. The purpose of this section is to present a 
narrative detailing the discoveries that highlights the contributions of the author to the 
field. 
 
4.1 Nonapoptotic Fas Signaling Causes T Cell Differentiation  
 
In order to investigate the possibility of a Fas/CD95 mediated effect on CD8+ T-cell 
differentiation, murine CD8+ naive T cells were purified through negative selection and 
stimulated with increasing amounts of recombinant human FasL ( leucine zipper FasL or 
lz-FasL) maintained in culture for 6 days (methods 7.1, 7.2, 7.8, and 7.9). After 6 days in 
culture the differentiation state of these cells was analyzed by flow cytometry (methods 7.3 
and 7.13) (Fig 7 A, B), with restimulation and intracellular staining performed in order to 
characterize interferon gamma release, which is a marker for effector capability.  
 
Given that this phenomenon could be explained by the selective deletion/apoptosis of 
naive and central memory cells in culture, suggested by the progressively lower cell yields 
with increased levels of lz-FasL (method 7.2) (Figure 7 C, D), the following experiment 
utilized two murine transgenic models of Fas loss of function (method 7.4). Lpr mice have 
no functional Fas receptor present, and C194V mice have a single mutation at the 194 site 
of Fas from Valine to Cysteine, which is published to nullify the apoptotic signal. If the 
hypothesis that a non-apoptotic signal conferred by Fas stimulation causes T-cell 
differentiation is correct, then treatment of C194V T cells may exhibit the differentiation 
phenotype but not the lpr T cells. If the lpr T cells revealed an effect, it would exist outside 
of the Fas signal. If there was not an effect in the C194V T cells, then the effect may be 
mediated along with the apoptotic signal.  
 
To analyze the effect of lz-FasL on cell death in these cells, CD8+ T cells were incubated 
for 6-8 hours with specified levels of lz-FasL and analyzed for PI and annexin positivity by 
flow cytometry (methods 7.3 and 7.9) (Figure 7 E). Following stimulation and culture for 6 
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days with and without Fas-lz, the differentiation states of the three strains were analyzed 
by flow cytometry and compared (methods 7.3) (Figure 7F). 
 
 
 
 
Figure 7 | Precocious differentiation is mediated by nonapoptotic Fas signaling. (A) 
Representative FACS plots and (B) bar graph summarizing the distribution of T cell subsets and 
IFN-γ production in isolated TN cells primed with CD3/CD28-specific antibodies, IL-2, and 
indicated doses of lz-FasL for 6 days prior to analysis. Data shown are based on n = 3              
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Figure 7… independently maintained cultures/conditions. (C) Relative overall cell yield and (D) 
relative cell yield of TEM or IFN-γ+ cells, normalized to no lz-FasL treatment, of TN-derived cells 
grown in the presence of titrated amounts of lz-FasL (C) or 33 ng/ml lz-FasL (D); data shown in C 
and D are based on n = 3–6 and n = 3 independently maintained cultures/condition, respectively. 
(E) Specific cell death of activated CD8+ T cells derived from WT (WT/WT), Lpr (lpr/lpr), and 
FasC194Vlpr/lprmice following exposure to titrated amounts of lz-FasL or a vehicle control; n = 
11 per condition/cell type. (F) Representative FACS plots demonstrating the frequency of TN-
derived cell subsets and (G) bar graph demonstrating fold increase in TEM phenotype cells after 
WT/WT, lpr/lpr, or FasC194Vlpr/lpr CD8+ T cells were expanded with CD3/CD28-specific 
antibodies and IL-2 alone or with 40 ng/ml of lz-FasL for 6 days; n = 6–9 independently 
maintained cultures/cell type. Statistical comparisons performed using an unpaired 2-tailed 
Student’s t test corrected for multiple comparisons by a Bonferroni adjustment. *P < 0.05; **P < 
0.01. Results are representative of 6 (A), 2 (C–E), and 4 (F and G) independently performed 
experiments and are displayed as mean ± SEM. Experiments performed and analyzed by Anthony 
Leonardi, Tori Yamamoto, and Christopher Klebanoff. Figure and legend used with permission 
from the Journal of Clinical Investigation (Klebanoff et al., 2016). 
 
As seen in Figures A, B, and D treatment of WT cells with Fas-lz induces a functional 
differentiation phenotype, as measured by the markers CD44, CD62L, and by cytokine 
release. Indeed, treatment of WT cells with Fas-lz will induce their death, but the 
differentiation phenotype is preserved in C194V mutant T cells lacking Fas-mediated 
apoptosis (Figures 7 E, F, G). Taken together, these experiments show that lz-FasL trimer 
induces cell differentiation and death in WT murine CD8+ T cells, differentiation in 
C194V CD8+ T cells, and has no effect on lpr CD8+ T cells. Furthermore, the data 
suggests the change in the population of cells in culture to Effector Memory is not due to 
selective deletion of Naive T cells, but rather differentiation, due to the lack of death 
observed in the C194V T cells. 
 
4.2 Fas Signaling Causes T Cell Differentiation in Human CD8+ T 
Cells 
 
As the effect seen in murine T cells may be exclusive to them and not human T cells, in 
order to investigate the effect of Fas signaling in human T cells, CD8+ Naive T cells were 
separated from PBMCs via negative selection, stimulated with OKT3 and CD28, and 
cultured for 7 days with lz-FasL or vehicle (methods 7.2, 7.8, and 7.9). Cells were 
analyzed by flow cytometry to assess their differentiation (method 7.3) (Figure 8 A, B). 
Since there are not C194V mutants where the apoptosis and differentiation effect can be 
teased apart, specific cell death was analyzed according to differentiation subset after 
treatment with Fas-lz (Figure 8 C, D). 
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Figure 8 | Fas signaling promotes the differentiation of human CD8+ T cells. (A) 
Representative FACS plots and (B) summary graph showing the distribution of CD8+ T cell 
subsets 7 to 10 days after peripheral blood CD8+ T cells from HD were stimulated with 
CD3/CD28-specific antibodies, IL-2, and indicated concentrations of lz-FasL. Results shown after 
gating on viable CD8+lymphocytes from n = 7 HD. TCM = CD8+CD45RO+CCR7+CD27+, TEM 
= CD8+CD45RO+CCR7–CD27–. (C) Representative FACS plots and (D) summary graph 
displaying the induction of lz-FasL specific cell death after gating on TCM and TEM cells 
stimulated with indicated concentrations of lz-FasL for 12 hours. Cells that coordinately stained for 
7-AAD and annexin V were considered apoptotic. Statistical comparisons performed using an 
unpaired 2-tailed Student’s t test corrected for multiple comparisons by a Bonferroni adjustment. 
*P< 0.05; **P < 0.01. Data shown are representative of 7 (A and B) and 2 (C and D) 
independently performed experiments with results displayed as mean ± SEM. Experiments 
performed and analyzed by Tori Yamamoto and Christopher Klebanoff. Figure and legend used 
with permission from the Journal of Clinical Investigation (Klebanoff et al., 2016). 
 
Taken together, when given that lz-FasL promotes the downregulation of CD27 and CCR7 
during cell culture in a titratable fashion (Figure 8 A, B), which is not dependent on a 
population-specific cell deletion via apoptotic induction (Figure 8 C, D), it can be 
concluded that Fas stimulation results in CD8+ T-cell differentiation in human cells.   
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4.3 Paracrine T-cell to T-cell Fas Signaling Causes T Cell 
Differentiation 
 
In order to test a possible role of FasL acting in a paracrine manner, a 1:1 coculture of 
Memory T cells stimulated with Naive T cells was made with use of congenic markers to 
track these two populations of cells (method 7.9). In the following experiment, naive alone, 
and naive and memory CD8+ murine T cells were stimulated with CD3/CD28 and cultured 
for 7 days with anti-FasL blocking antibody or IGG (methods 7.2, 7.4, 7.8, and 7.9). After 
6 days of coculture, phenotypes of the cells were analyzed by flow cytometry (method 7.3) 
(Figure 9A) and subset differences calculated between groups (Figure 9B). In order to 
measure effector function, cells were restimulated on Day 6 and measured for effector 
cytokine release (method 7.3) (Figure 9C). In order to test the possibility the paracrine 
differentiation effect was not FAS dependent, Naive Fas deficient T cells were 
concurrently cocultured with WT Memory T cells as described and analyzed by flow 
cytometry (methods 7.2, 7.3, 7.4, 7.8, 7.9, and 7.18) (Figure 9D). 
 
 
 
Figure 9 | Paracrine T-cell to T-cell Fas Signaling Causes T Cell Differentiation. (A) 
Representative FACS plots, (B) summary bar graph, and (C) scatter plot demonstrating T cell 
subset frequencies or percentage of IFN-γ+CD8+ T cells 6 days following priming of Ly5.1+ TN 
alone or in a 1:1 mixture with Ly5.2+ TMem with CD3/CD28-specific antibodies, IL-2, and a 
blocking antibody against FasL (αFasL) or isotype (IgG) control. (D) FACS analysis and (E) bar 
graph summarizing the distribution of CD8+ T cell subsets 6 days following priming of Ly5.2+ 
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Figure 9…WT TN pmel-1 (TNWT/WT) or lpr/lpr TN pmel-1 (TNlpr/lpr) cells alone or in the 
presence of a 1:1 mixture with WT Ly5.1+ TMem. All results shown as mean ± SEM with n = 2–3 
per indicated condition or cell type. Statistical comparisons performed using an unpaired 2-tailed 
Student’s ttest corrected for multiple comparisons by a Bonferroni adjustment. *P < 0.05; **P < 
0.01; ***P < 0.001. Data shown are representative of 14 (A and B), 4 (C), and 3 (D and E) 
independently performed experiments. Experiments performed and analyzed by Anthony Leonardi 
and Christopher Klebanoff. Figure and legend used with permission from the Journal of Clinical 
Investigation (Klebanoff et al., 2016). 
 
This experiment reveals that T cells have the ability to cause differentiation in a paracrine 
manner, where lz-FasL expressed by memory T cells may act upon lesser differentiated 
counterparts and push them toward effector status, which can be abrogated with a lz-FasL 
blocking antibody (Figure 9 A, B, C). Given the absence of the effect when the naive T 
cell population does not express a functional Fas receptor as is the case in lpr/lpr mice, this 
phenomenon can be concluded to be a Fas- mediated effect, and not an effect of lz-FasL or 
lz-FasL on another receptor (Figure 9 D, E). 
 
 
4.4 Fas-mediated Differentiation is Dependent Upon AKT 
 
To determine whether the differentiation that is conferred by the paracrine FasL signalling 
is AKT dependent, naive WT murine CD8+ T cells were stimulated and cultured for 24 
hours with and without the presence of memory T cells (methods 7.2, 7.4, 7.8, and 7.9). 
These cells were analyzed by flow cytometry for phosphorylation at residues T308 and 
S473 on AKT and S6 Kinase and their Mean Fluorescence Intensities compared to baseline 
(method 7.3) (Figure 10 A, B, C). To investigate a possible change in genes associated 
with lymphocyte maturation, expression levels were analyzed and compared during 
stimulation (Figure 10D). In order to analyze the effect of CD95 signaling without memory 
T cells, to be sure the effect on AKT in the naive cells was not mediated by cytokines or 
other agents the memory T cells, naive WT murine CD8+ T cells were stimulated with 
indicated amounts of lz-FasL with AKT inhibitor or vehicle (method 7.9). 24 hours after 
stimulation, cells treated with titrating amounts of lz-FasL were analyzed for AKT T308 
phosphorylation by western blot (method 7.14) (Figure 10E). At day 6 following 
stimulation, cells were analyzed by flow cytometry for 2-NBDG uptake to measure 
glycolytic metabolism as indicated by sugar uptake (method 7.3) (Figure 10 F, G) which is 
associated with increased differentiation and effector function. To determine whether the 
differentiation signal from lz-FasL can be abrogated with an AKT inhibitor, cells treated 
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with lz-FasL and AKT inhibitor were analyzed by flow cytometry for differentiation 
marker expression (method 7.3) (Figure 10H) and effector cytokine release following 
restimulation, with comparison of the subsets (Figure 10I) and the cytokine release 
(method 7.18) (Figure 10J).   
 
 
 
 
Figure 10 | Precocious differentiation is associated with augmented AKT signaling. 
Representative FACS histograms and summary bar graphs demonstrating the mean fluorescence 
intensity of (A) pAKT T308, (B) pAKT S473, and (C) pS6 in Ly5.2+CD8+ TN cells at rest or 24 
hours after stimulation with CD3/CD28-specific antibodies alone or in a 1:1 mixture with Ly5.1+ 
TMem cells. Data shown after gating on live+Ly5.2+CD8+ cells. (D) RMA-normalized intensity 
Figure 10… showing expression of Il7ra, S1pr1, Tfrc, Hk2, and Slc2a1 in resting TN cells, TN 
cells primed alone, and TN cells primed in a 1:1 mixture with TMem cells. (E) Western blot and 
densitometry analysis of pAKT T308 and GAPDH in resting TN or TN cells primed for 24 hours 
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Figure 10… with CD3/CD28-specific antibodies and titrated doses of lz-FasL. (F) Representative 
FACS plot and (G) summary scatter plot showing 2-NBDG expression in TN cells primed alone 
for 6 days with CD3/CD28-specific antibodies, IL-2, and lz-FasL (50 ng/ml) or vehicle control. 
Data shown after gating on live+CD8+ lymphocytes. (H) Representative FACS plots, (I) summary 
bar graph demonstrating the frequency of CD8+ T cell subsets, and (J) scatter plots showing IFN-γ 
production in TN cells primed with CD3/CD28-specific antibodies, IL-2, and lz-FasL (50 ng/ml) in 
the presence or absence of an inhibitor of AKT1/2 (AKTI) for 6 days. Statistical comparisons 
performed using an unpaired 2-tailed Student’s t test corrected for multiple comparisons by a 
Bonferroni adjustment. *P < 0.05; **P < 0.01; ***P < 0.001. All data shown are displayed as 
mean ± SEM. Experiments performed with n = 3 per condition/time point in A–D and F–J. All 
data shown are representative of 2 independently conducted experiments. Experiments performed 
and analyzed by Anthony Leonardi, Tori Yamamoto, Robert Eil, and Christopher Klebanoff. 
Figure and legend used with permission from the Journal of Clinical Investigation (Klebanoff et al., 
2016). 
 
 
These data reveal that the differentiation induced by memory cells on naive cells results in 
the phosphorylation (activity of AKT) at residues T308 and S473, and the activation of 
pS6 which is associated with increased metabolism, giving the possibility these cells will 
be more glycolytic (Figure 10 A, B, C). Additionally, these effects on differentiation are 
congruent with the mRNA levels of differentiation-related genes (Figure 10D). 
Furthermore, this effect on the phosphorylation state of AKT can be seen by western blot 
with use of lz-FasL in lieu of memory cells (Figure 10E) with an effect seen additionally 
on glucose uptake (Figure 10 F, G). The necessity of AKT signaling to propagate the 
differentiation induced by lz-FasL is also maintained (Figure 10 H, I, J). To summarize the 
data thus far, paracrine Fas- mediated differentiation is AKT dependent, and Fas-induced 
differentiation also increases the glycolytic activity of cells. 
 
4.5 Fas Signaling Controls T Cell Differentiation and Attenuates 
Adoptive Immunotherapy Efficacy 
 
In order to test the efficacy of T cell populations with and without Fas signaling in a 
tumor-treatment model of adoptive immunotherapy, murine Pmel-1 CD8+ T cells were 
stimulated as described (methods 7.2, 7.4, 7.8, and 7.9) in groups consisting of Naive 
CD8+ T cells alone, Naive CD8+ T cells with lz-FasL, Naive and memory CD8+ T cells in 
a 1:1 mixture with IGG antibody, and Naive and memory CD8+ T cells in a 1:1 mixture 
with anti-FasL blocking antibody. After culture expansion, B16 melanoma tumor-bearing 
mice were treated with a 6 Gy dose of radiation, intravenous rVV-gp100, and infused with 
2.5 x 105 cells (method 7.7). IL-2 support was administered intraperitoneally once a day 
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for three days, and tumors were measured at least once every three days (method 7.7) 
(Figure 11A). Following the experiment, survival was plotted and measured between 
conditions (Figure 11B). Given that a change in efficacy could be due to the failure of 
adoptively transferred lz-FasL treated T cells to engraft in the host, 18 hours after infusion, 
a small amount of blood was taken from the tail vein of mice and the proportion of Pmel-1 
CD8+ lymphocytes was measured by flow cytometry (method 7.1, 7.3) (Figure 11C). To 
illustrate the effect between CD62L expression and efficacy of adoptively transferred cells, 
a linear regression analysis was performed (method 7.18) (Figure 11D). 
 
 
 
Figure 11 | Fas signaling controls T cell differentiation and influences adoptive 
immunotherapy efficacy. (A) Tumor regression and (B) animal survival of mice bearing 10-day 
established s.c. B16 melanomas treated with 2.5 × 105 TN-derived pmel-1 cells primed alone, with 
lz-FasL (50 ng/ml), or with TMem in the presence of αFasL or IgG control. Viable cells were 
isolated using a density separation media before infusion. All treated mice received 6 Gy 
irradiation prior to cell infusion in addition to i.v. rVV-gp100 and 3 days of i.p. IL-2. Tumor 
treatment experiments performed with n = 5 mice/group. TMix, TN cells primed with TMem cells 
in a 1:1 mixture. (C) Engraftment efficiency of Thy1.1+ TN-derived pmel-1 cells (3 × 105) primed 
alone or with lz-FasL 18 hours following i.v. adoptive transfer into nonirradiated Ly5.2+ hosts; n = 
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Figure 11… mice/group. (D) Correlation between the slope of tumor growth and CD62L 
expression at the time of cell transfer on TN-derived pmel-1 cells primed alone with either lz-FasL 
(50 ng/ml), vehicle control, or with TMem and either αFasL or IgG. Pooled results from 2 
independently performed experiments displayed using n = 4–10 mice per condition. Statistical 
comparisons performed using an unpaired 2-tailed Student’s t test or log-rank test for animal 
survival. *P < 0.05. Data shown are representative of 2 independent experiments with results 
displayed as mean ± SEM. Experiments performed and analyzed by Anthony Leonardi and 
Christopher Klebanoff. Figure and legend used with permission from the Journal of Clinical 
Investigation (Klebanoff et al., 2016). 
 
Given the results of this data, abrogation of Fas signaling in heterogenous populations of T 
cells which contain naive and memory subsets is beneficial as measured by the efficacy of 
tumor immunotherapy (Figure 11 A, B). Furthermore, attenuation seen in the therapy by 
the addition of lz-FASL to naive cultures is not due to an engraftment failure (Figure 5C). 
Interestingly, the rate of tumor growth, or tumor slope, is correlated with the CD62L 
expression of the T cells used prior to infusion (Figure 11D). Taken altogether, Fas 
inhibition represents a novel efficacious method of enhancing the efficacy of tumor 
immunotherapy, as demonstrated in a murine model. 
 
4.6 AKT Inhibition prevents differentiation of T cells 
 
To test the phenotype conferred to T cells stimulated and cultured while under AKT 
inhibition, human T cells were isolated from blood, stimulated with anti-CD3 (OKT3) in 
IL-2 containing media with and without AKT inhibitor, and transduced with the CD19 
CAR on Day 2, and cultured until day 10 (method 7.10) (Figure 12A) (Klebanoff et al., 
2017). In order to understand the pathways affected by inhibition, groups were stained for 
phosphorylation state of specific signaling proteins at three timepoints: before stimulation, 
and 5 and 10 minutes following stimulation at points in the AKT/mTOR pathways (Figure 
1B) and MAPK pathway (method 7.12) (Figure 12C). Following a culture period of 10 
days, the cell expansion was calculated and compared between groups (method 7.18) 
(Figure 12D), and transduction efficiency (Figure 12E) and CD62L expression (Figure 
12F, G) was analyzed by flow cytometry (method 7.12). 
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Figure 12 |Pharmacologic inhibition of AKT signaling permits expansion of CD62L-
expressing receptor-engineered human peripheral blood T cells. (A) Schema for the anti-CD3 
(50 ng ml–1) activation, retroviral transduction (RV Td), and expansion of human peripheral blood 
T lymphocytes (PBL) in the continuous presence of IL-2 (300 IU ml–1) and AKT inhibitor VIII 
(AKTi; 1 µM) or vehicle control (Veh). (B) Representative phosphoflow cytometry plots and (C) 
graphical summary of the time-dependent phosphorylation of kinases involved AKT/mTOR or 
MAPK signaling in PBL expanded in the presence or absence of AKTi immediately prior to and 
following stimulation with an anti-CD3 antibody. Results from 1 of 2 representative experiments 
are displayed. (D) Fold expansion and (E) transduction efficiency of unfractionated PBL 
genetically engineered with a second-generation 28z anti-CD19 chimeric antigen receptor (CAR) 
following ex vivo expansion over 10d in the continuous presence IL-2 and AKTi or Veh. Pooled 
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Figure 12… results from 6 independent donors are shown after gating on viable, transduced 
CD3+CD4+ and CD3+CD8+ cells. (F) Representative FACS plot and (G) graphical summary of 
CD62L expression on CAR-modified PBL expanded for 10d in AKTi or Veh control. Results 
shown in panels D–G are based on patient-derived samples, while results in panels B and C used 
healthy donor (HD) T cells. Data in panels C–E and G are presented as mean ± SEM with n = 3, n 
= 6, n = 6, and n = 3 per condition, respectively. All statistical comparisons were performed using 
an unpaired 2-tailed Student’s t test. ***P < 0.001; **P < 0.01; *P < 0.05. Experiments performed 
and analyzed by Joseph Crompton, Robert Eil, and Christopher Klebanoff. Figure and legend used 
with permission from JCI Insight (Klebanoff et al., 2017). 
 
Interestingly, the data revealed as expected the AKT and mTOR pathways were affected as 
measured by phosphorylation status by the AKT inhibitor, but the MAPK/ERK pathway 
was unaffected by the addition of AKT. (Figure 12 B,C). As the MAPK pathway is 
required for cell survival and proliferation, this would allow for cells to continue 
expanding and multiplying at normal rates, as seen in Figure 12 D. As the retrovirus used 
for transduction requires cells to be proliferating for optimal rates, likely due to the 
unhindered proliferation between groups there was also no difference in the CD19 CAR 
transduction between them (Figure 12E), however the phenotype difference of CD62L 
expression, which denotes greater memory and less differentiation was indeed significantly 
discrepant (Figure 12 F, G). Taken together, this evidence strongly suggests AKT 
inhibition enables cell proliferation while holding back cell differentiation by holding back 
the AKT/mTOR pathways and leaving MAPK unperturbed. 
 
4.7 AKT Inhibition Lowers Glycolytic Activity of CAR-T Cells 
 
Given the observation that the metabolic state of CAR-T cells correlates with tumor-
treatment response (Kawalekar et al., 2016), the metabolic state of AKT treated cells was 
further characterized in order to determine fitness. T cells from healthy human donors were 
isolated, stimulated, and transduced with the CD19 CAR as described (method 7.10). 
Following 5 days of stimulation and culture, cells were harvested and assayed via 
metabolomic analysis to observe the levels of intracellular metabolites (method 7.15) 
(Figure 13 A, B) and analyzed by flow cytometry for 2-NBDG uptake after co-incubation 
(method 7.15) (Figure 13C). Cells treated with AKT inhibitor or vehicle were plotted by 
their principal components in principal component analysis (PCA) revealed by 
metabolomic analysis (method 7.15) (Figure 13A), and lactate production (Figure 13B). To 
test if the genes associated with glycolysis were changed in expression and function by 
AKT inhibition, CD19 CAR-T cells were cultured for 10 days and analyzed by seahorse 
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for their extracellular acidification rate (ECAR) (method 7.15) (Figure 13D) and also 
analyzed by mRNA for expression of key metabolic genes involved in glycolysis and 
lactate transport (method 7.14) (Figure 13E). 
 
  
 
 
Figure 13 | AKTi limits the acquisition of a glycolytic metabolism in human peripheral blood 
T cells transduced with an anti-CD19 CAR. (A) Two-dimensional principal component analysis 
(PCA) visualizing the variation in 308 metabolites detected using a metabolomic assay in anti-
CD19 chimeric antigen receptor (CAR) transduced T cells expanded in AKTi or vehicle control 
(Veh). Percentages indicate the amount of variance captured within each principal component. 
Results are shown from 3 independently evaluated donors using the average of n = 5 replicates per 
condition and donor. (B) Ratio of lactate, an end glycolytic intermediate, detected in anti-CD19 
CAR transduced T cells expanded in the continuous presence of AKTi versus Veh. The mean ratio 
± SEM from n = 3 independently evaluated donors is shown with the dashed line indicating a 
lactate ratio of 1. (C) 2-(N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl]amino)-2-deoxyglucose (2-NBDG) 
uptake and (D) extracellular acidification rate (ECAR) 5d after stimulation and expansion of 
peripheral blood T cells in the continuous presence of AKTi or Veh control. Results shown in panel 
C are representative of 3 independently performed experiments; results in panel D are based on 
cultures from n = 4 independently evaluated donors. (E) Heat map of gene expression for the 10 
enzymes involved in glycolysis and the 2 primary lactate exporters, LDHA and SLC16A3, found in 
lymphocytes. Each column represents the average expression of a gene from 3 independently 
evaluated patient donors, and each row represents the indicated gene. Red and blue colors indicate  
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Figure 13… relative increased and decreased expression, respectively. Data shown in panels A, B, 
and E are from patient-derived T cells, and panels C and D are from healthy donors (HDs). 
Statistical comparisons in panels C and D were performed using an unpaired 2-tailed Student’s t 
test. ***P < 0.001; *P < 0.05. Experiments performed and analyzed by Anthony Leonardi, Madhu 
Sukumar, Joseph Crompton, and Christopher Klebanoff. Metabolomics performed by Metabolon 
Corporation. Figure and legend used with permission from JCI Insight (Klebanoff et al., 2017). 
 
As revealed by the data, CAR-T cells treated with the AKT inhibitor have a consistent 
metabolic signature and cluster in PCA (Figure 13A). These cells also produce less lactate 
(Figure 13B) and consume less glucose (Figure 13C) compared to vehicle treated cells. As 
seahorse ECAR analysis measures hydrogen proton concentration in the media as it is 
released from T cells, it is used as an indirect measurement of lactate and glycolytic flux, 
which the data revealed AKT treated CD19 CAR-T cells to be significantly less reliant on 
acidic metabolic pathways (Figure 13D). Indeed, AKT treated cells had significantly less 
expression of glycolytic enzymes (Figure 13E). Taken on the whole, these data reveal that 
AKT treatment increases the metabolic fitness of T cells used for CD19 CAR-T therapy, 
which correlates with tumor response (Kawalekar et al., 2016). 
 
4.8 AKT Inhibition Withholds T Cell Differentiation and Promotes 
FOXO1 Nuclear Localization 
 
Given the pronounced changes in differentiation phenotypes associated with AKT 
inhibition, a more comprehensive approach to categorizing the genetic program changes 
was taken. Human CD19 CAR-T cells were manufactured as described previously through 
isolation from peripheral blood, stimulation with OKT3 and anti-CD28, and retroviral 
transduction in the presence of AKT inhibitor or vehicle (method 7.10). Transcriptomic 
analysis was performed on day 10, which yielded a consistent pattern of gene clustering for 
AKT treated, untreated, and baseline control groups (method 7.16) (Figure 14A). 
Differential expression of top genes from transcriptomic analysis were listed, many 
directly correlating with T cell differentiation and phenotypic markers, including SELL, 
which encodes CD62L (Figure 14B). These differentially expressed genes were grouped 
under categories of interest including genes which are controlled by a single transcription 
factor (FOXO1), genes encoding costimulatory proteins, genes encoding effector 
molecules, and genes involved in apoptosis (Figure 14B). mRNA analysis of expression 
levels of genes specifically associated with effector function and differentiation was 
performed (method 7.16) (Figure 14C). As AKT inhibition created a discrepant expression 
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profile of many genes responsible for differentiation phenotype which are under control of 
the transcription factor FOXO1, and since AKT has been shown in cancer cell lines to 
inactivate FOXO1 via phosphorylation which traps FOXO1 in the cytosol and prevents 
migration to the nucleus, confocal microscopy was performed in order to localize the 
FOXO1 in AKT treated and untreated cells to the nucleus by permeabilizing the membrane 
of the cells and incubating with FOXO1 specific antibody (labeled with hoescht) or 
cytoplasm (labeled with phalloidin), the labeled with a secondary fluorescent antibody 
targeting the FOXO1 primary (method 7.17) (Figure 14D). The ratios of nuclear vs. 
cytoplasmic concentrations of FOXO1 were calculated (Figure 14E), and the expression 
level of FOXO1 between groups was also measured in order to determine if it was a factor 
in any cytosolic vs. nuclear differences observed (methods 7.17, 7.18) (Figure 14F). 
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Figure 14 | Blockade of AKT signaling minimizes gene expression changes associated with 
human T cell differentiation and promotes nuclear accumulation of the transcription factor 
FOXO1. (A) Unsupervised hierarchical clustering of gene expression from peripheral blood T cells 
at baseline and 10d after stimulation, retroviral transduction (RV Td) with an anti-CD19 chimeric 
antigen receptor (CAR), and expansion in the continuous presence of IL-2 (300 IU ml–1) and AKT 
inhibitor VIII (AKTi; 1 µM) or a vehicle control (Veh). Clustering was based on all significantly 
expressed genes (1-way ANOVA, FDR-corrected P < 0.05) using a Pearson correlation. T cells 
were derived from 3 independent donors using an n = 3–4 replicates per donor, per time point, and 
per condition. (B) Heat map of expression for selected genes that are direct targets of the 
transcription factor FOXO1 or genes involved in T cell costimulation, effector function, and 
apoptosis. Red and blue colors indicate relative increased and decreased expression, respectively. 
Each column represents the average expression of a gene from an individual donor, and each row 
represents the indicated gene. (C) Robust multichip analysis–normalized (RMA-normalized) 
intensity of selected FOXO1-target genes and genes associated with T cell differentiation at  
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Figure 14… baseline and 10d after ex vivo expansion in the continuous presence of AKTi or Veh. 
The bar graphs represent the mean ± SEM of n = 3 overlaid biological replicates per condition from 
a single donor and are representative of experiments observed with all 3 independently analyzed 
donors. (D) Representative confocal immunofluorescence images and (E) summary graph 
quantifying the dose-dependent intranuclear accumulation of FOXO1 4d following T cell 
activation and expansion in indicated concentrations of AKTi or Veh control. Red, FOXO1; blue, 
Hoechst; and green, phalloidin. Scale bar: 10 µm. Data shown are representative of 2 independently 
performed experiments using 2 separate donors. (F) The ratio of gene expression levels for FOXO1 
in AKTi- versus Veh-treated cells from n=3 independently evaluated donors. Dashed horizontal 
line indicates an expression ratio of 1. Data shown in panels A–C and F are from patient-derived T 
cells, and panels D and E are from healthy donors (HDs). Statistical comparisons in panels C and E 
were performed using an unpaired 2-tailed Student’s t test corrected for multiple comparisons by a 
Bonferroni adjustment. ***P < 0.001; **P < 0.01; *P < 0.0167. Experiments performed and 
analyzed by Anthony Leonardi, Joseph Crompton, and Christopher Klebanoff. Figure and legend 
used with permission from JCI Insight (Klebanoff et al., 2017). 
 
Taken together, there is a consistent genetic program exhibited by treating CD19 CAR-T 
cells with an AKT inhibitor during stimulation and expansion with a differentiation profile 
that is pertinent to FOXO1. Furthermore, AKT’s effect of cytoplasmic sequestration on 
FOXO1 can be abrogated by inhibiting AKT activity, as demonstrated by confocal 
microscopy. Based on this conclusion, it would be worth investigating whether the 
enforced activity of FOXO1 can overcome AKT’s inhibitory effect on nuclear localization, 
and create a memory phenotype. 
 
4.9 FOXO1 Expression Confers a Lesser-Differentiated T-cell 
Phenotype 
 
Given that AKT can affect FOXO1 activity via phosphorylation at the T24, S256, and 
S319 residues, a mutant FOXO1 gene (FOXO1AAA) was engineered by substituting 
Alanine at these residues which cannot be phosphorylated, and encoded into a retrovirus in 
order to enforce expression of FOXO1AAA (Figure 15 A, B). FOXO1AAA should remain 
unaffected by AKT due to the lack of AKT-dependent phosphorylation sites. Since 
FOXO1 is in control of the differentiation markers in an AKT-dependent manner, a 
discrepancy should be seen among AKT-dependent markers of differentiation between 
cells transduced with FOXO1AAA and control (empty) vector. To begin the experiment, 
PBMC from an individual human donor was isolated, stimulated with and without AKT 
inhibitor for each type of transduction, and transduced with the Retrovirus for FOXO1AAA 
alongside a group transduced with an empty vector with the congenic marker thy1.1 
(method 7.10). Cells were analyzed by flow cytometry 5 days after stimulation for genes 
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associated with effector function and differentiation, and gated on the cells which were 
positive for the congenic marker thy1.1, denoting successful transduction (method 7.12) 
(Figure 15C). The percentage of specific subsets for each condition were determined 
through flow cytometry and compared (method 7.19) (Figure 15D). 
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Figure 15 | Expression of a constitutively active form of FOXO1 augments CD62L expression 
independently of AKTi. (A) Schematic diagram of WT human FOXO1 protein highlighting 3 
serine/threonine residues that serve as AKT phosphorylation sites and an alanine substituted variant 
(FOXO1AAA) refractory to AKT phosphorylation. Shaded boxes represent specific functional 
domains within the FOXO1 protein. FHD, forkhead domain; NLS, nuclear localization signal; 
NES, nuclear export signal; TAD, transcriptional activation domain. (B) Schematic illustration of 
the MSGV retroviral constructs containing FOXO1AAA and a Thy1.1 reporter separated by a T2A 
ribosomal skip sequence (FOXO1AAA-T2A-Thy1.1) or an empty vector Thy1.1 (Empty-Thy1.1) 
control. (C) Expression of CD62L, CD28, LAG3, PD1, and TIM3 on Thy1.1-gated T cells 5d after 
stimulation and retroviral transduction with FOXO1AAA-T2A-Thy1.1 or Empty-Thy1.1 control in 
the presence or absence of AKTi (1 µM) and IL-2 (300 IU ml–1). Results from 1 of 2 
representative experiments are shown. (D) Summary bar graphs and overlaid individual data points  
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Figure 15… showing the distribution of TCM and TEM subsets in T cells expanded in the 
presence or absence of AKTi following transduction with FOXO1AAA-T2A-Thy1.1 or Empty-
Thy1.1. Each bar graph represents the mean ± SEM of independent replicates from n = 8 
independently performed experiments using healthy donor (HD) T cells. Statistical comparisons 
performed using an unpaired 2-tailed Student’s t test corrected for multiple comparisons by a 
Bonferroni adjustment. ***P < 0.001; **P < 0.01; *P < 0.0167. Experiments performed and 
analyzed by Anthony Leonardi, Smita Chandran, and Christopher Klebanoff. Figure and legend 
used with permission from JCI Insight (Klebanoff et al., 2017). 
 
According to the data from this experiment, there is a FOXO1-dependent increase of 
CD62L expression even without the addition of AKT inhibitor, in the group of T cells 
transduced with FOXO1AAA even when compared to AKT inhibition alone (Figure 15D). 
Furthermore, FOXO1AAA transduction combined with AKT inhibition did not have an 
increased effect on retaining the memory phenotype when compared to AKT inhibition 
alone. Given the dominant effect of FOXO1AAA, this data supports the conclusion that the 
abrogation of AKT mediated differentiation by use of the AKT inhibitor is FOXO1 
dependent. 
 
4.10 AKT Inhibition Augments CAR-T Cell Adoptive Immunotherapy 
 
Given the benefits to metabolism and differentiation seen with the treatment of AKT 
inhibitor, testing the human CD19 CAR-T cells treated by AKT inhibitor in a xenograft 
model was performed to directly compare the in vivo tumor-killing efficacy of the cells. As 
described previously, human lymphocytes were isolated, stimulated, transduced with the 
CD19 CAR, and grown in the presence of AKT inhibitor or vehicle (method 7.10). These 
cells were then transferred at a rate of 1 X 106 into immunodeficient NOD scid γ (NSG) 
mice bearing acute lymphoblastic leukemia (ALL) as described (method 7.5, 7.6). Tumors 
were visualized using a luciferase reporter gene they expressed which was visualized by in 
vivo bioluminescent imaging (method 7.5) (Figure 16A). 35 days after treatment, survival 
was compared between groups (method 7.18) (Figure 16B). 
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Figure 16 | Anti-CD19 CAR–modified T cells expanded in the presence of AKTi treat 
established leukemia superiorly to conventionally grown T cells. (A) In vivo bioluminescent 
imaging and (B) overall survival of NOD scid γ (NSG) immunodeficient mice bearing established, 
systemic, NALM6-GL leukemia xenografts following adoptive transfer of anti-CD19 chimeric 
antigen receptor–modified (anti-CD19 CAR–modified) peripheral blood T cells expanded in the 
presence of AKTi (1 µM) or vehicle (Veh) control. Data shown in panel A is from T cells using a 
patient donor that is representative of findings in all 3 patient donors; data shown in panel B are the 
pooled survival results from n = 4–5 mice per condition per donor using cells derived from 3 
patient donors. Differences in overall survival were determined using the Mantel-Cox test. ***P < 
0.001; *P < 0.05. Experiment performed and analyzed by Luca Gattinoni, Yun Ji, and Christopher 
Klebanoff. Figure and legend used with permission from JCI Insight (Klebanoff et al., 2017). 
 
Given the significantly increased survival benefit of mice bearing ALL in a CD19 CAR-T 
xenograft model, it can be concluded that AKT inhibition yields CAR-T cells which are 
superior in tumor treatment efficacy, justifying the superior measurements of fitness by 
phenotypic markers of differentiation and metabolism. 
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5 COHESIVENESS OF THE PUBLICATIONS 
 
The excerpted figures from the author’s publications presented here represent a linear 
mechanism in T cell differentiation and its use to better the adoptive immunotherapy of 
cancer. As the datasets and narratives surrounding the findings that 1) T-cells differentiate 
via AKT (Leonardi and Crompton, 2012, Crompton et al., 2015, Klebanoff et al., 2017) 
and 2) T-cells differentiate via Fas (Leonardi AJ, 2012, Klebanoff et al., 2016) are vast, 
they expand several publications and represent four years of full-time investigation and 
employment at the NIH. Taking these findings and publications which span 5 years, three 
posters, and three separate papers into account, a stepwise pathway of T cell differentiation 
can be traced from T cell activation, to CD95 costimulation, to AKT phosphorylation, to 
the direct inhibition of the transcription factor FOXO1 which directly causes a 
memory/naive phenotype via expression of CD62L (Leonardi and Crompton, 2012, 
Leonardi AJ 2012, Yamamoto et al., 2015, Crompton et al., 2015, Klebanoff et al., 2016, 
Klebanoff et al., 2017). The figures presented in this thesis aim to highlight the linearity 
and logical progression of the discoveries. The discovery that AKT inhibition bettered T 
cells for adoptive immunotherapy, and the discovery that Fas signaling caused T cells to 
differentiate were both presented internally within the NIH by the author in 2012, and not 
published externally until 2015, 2016, and 2017. As there was an opportunity in 
commercialization of the invention of Fas blockade in T cells for adoptive immunotherapy, 
an invention report was issued by the National Institutes of Health detailing the application 
of the finding in 2012.  
 
The points of intervention for withholding T cell differentiation presented in this work act 
in concordance. To be specific, the publication in January 2016 in JCI reveals that the 
signal caused by CD95 stimulation is propagated through AKT (Klebanoff et al., 2016, 
Figure 7). These mechanistic studies allow for the categorization of the Fas differentiation 
signal as a kind of co-stimulation upstream of the AKT signaling event, where the AKT-
mediated differentiation signal can be attenuated with an AKT inhibitor, or prevented with 
antibody blockade of CD95L (Klebanoff et al., 2016). The data published in 2017 in JCI 
insight is a further development and application of the AKT project as pertaining to CAR-
T cells (Klebanoff et al., 2017). In it, the pathway following AKT signaling is explored and 
the direct influence of AKT on transcription factors and their role in cell differentiation 
48 
 
uncovered, specifically by use of FOXO1 transduction, which is a transcription factor 
directly inhibited by AKT (Klebanoff et al., 2017, Figure 3).  
 
Other publications by the author outside of the FAS and AKT project have similar goals in 
targeting tumor necrosis factor (TNF) family members in immunotherapies. For example, 
since TNF family members may be associated with toxicity following adoptive cell 
transfer, they may be antagonized during adoptive immunotherapy, as proposed in a 
recently published patent application (Leonardi AJ, 2018).  
 
Other publications seek to optimize T cell function after adoptive transfer. The use of IL-
12 in adoptive immunotherapy was such an effort, although it did not focus on the 
differentiation of T cells but rather their function in the tumor microenvironment (Kerkar 
et al., 2011). The use of ATRA as a conditioning regimen for T cell infusion related to T 
cell function and dendritic cell fate in tumor immunotherapy (Klebanoff et al., 2013).  
 
In summary, all publications listed in this thesis pertain to fine-tuning T cell function for 
the immunotherapy of cancer. 
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6 CONTRIBUTION TO THE FIELD 
 
This section will detail the two major contributions to the field made by the author, which 
have been reflected by the data and figures shown in the thesis. These contributions 
include the use of AKT inhibition in Adoptive T cell therapy and the paracrine 
differentiation of T cells by CD95 signaling. Altogether, the author has been cited 474 
times for the sum of work in tumor immunotherapy (Fig. 15). 
 
Figure 17 | Number of Citations of the Author’s work 
 
 
6.1 Use of AKT Inhibition in Adoptive T-Cell Therapy 
 
The uncoupling of differentiation from proliferation and culture expansion is an invaluable 
ability in adoptive T cell immunotherapy (Crompton et al., 2014). Therapeutic outcomes 
are greatly affected by the level of differentiation and proliferative capacity of the T cells 
used (Rosenberg et al., 2011, Klebanoff and Gattinoni, 2012). The addition of a single 
small molecule to cell culture represents an unrivaled level of ease of implementation. As 
such, academic and commercial entities have quickly adopted the addition of an AKT 
inhibitor to T cell cultures for adoptive immunotherapy, with the first publication an 
internal poster session in the NIH for postbaccalaureate research fellows in 2012 (Leonardi 
and Crompton, 2012). As of April 2018, the first external publication in 2015 detailing use 
of AKT inhibition for adoptive T cell therapy has been cited 96 times in literature 
catalogued by pubmed, exceeding the typical impact factor of papers in the journal by four 
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times (Crompton et al., 2015). To its credit, the inhibition of AKT is used in one of the two 
FDA approved CAR-T methods of adoptive cell therapy; Yescarta®, developed by KITE 
Pharma (Johnson and June, 2017). Other companies focused on bringing CAR-T products 
to market also use AKT inhibitor, like Bluebird Bio, but their therapies are yet to receive 
approval for use (Perkins, et al., 2015).  
 
 
6.2 T-cell Differentiation Through a non-apoptotic CD95 Signal 
 
An understanding and delineation of the factors contributing to T cell differentiation had 
been elusive before the role of CD95 was uncovered (Klebanoff and Gattinoni, 2012). Just 
before the finding, it was noted that CD95 positivity was a marker for naive-like cells with 
high proliferative and self-renewing capacity (Gattinoni et al., 2011). The data presented in 
this thesis and the publications that followed, ascribe a central function to CD95 rather 
than a simple marker in the life cycle of a T cell (Leonardi AJ 2012, Klebanoff et al., 
2016). Before, Fas was considered a canonical death receptor when pertaining to T cell 
function (Waring and Müllbacher, 1998). Now, a dual role has been delineated, showing 
naive and memory T cells have a tendency to differentiate with a Fas signal until they 
adopt an effector phenotype (Klebanoff et al., 2016). With further agonization of CD95 as 
an effector cell, they will then apoptose rather than remaining as memory (Klebanoff et al., 
2016). 
 
The publication in 2016 detailing the CD95 differentiation phenotype has been cited 53 
times, more than twice that of other papers in the Journal of Clinical Investigation. These 
citations explore the concept of optimizing T cell function to better adoptive 
immunotherapy of cancer.  A more direct application of this finding came from 
collaborators to the original work in the lab of Dr. Richard Siegel. Taking into account the 
information we passed to them in regard to this finding, they verified that patients with 
Autoimmune Lymphoproliferative Syndrome (ALPS), which is a syndrome where Fas is 
mutated, have T cells which are lower in AKT activity and do not differentiate when 
treated with Fas Ligand Trimer, contrary to normal T cells (Cruz et al., 2016). This is a 
novel insight into the pathogenesis of ALPS, but the finding has yet to translate into 
treatment due to lack of a point of reasonable mechanistic intervention. 
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6.3 Concluding Remarks and Future Consideration 
 
The field of adoptive immunotherapy of cancer is rapidly growing, propelled by 
advancements that make the method more efficacious. It is now at the maturity to where it 
has become a viable method in the treatment of widely disseminated metastatic disease 
such as leukemias and lymphomas. Stepwise advances pertaining to the T cell’s function 
are the “effector” arm of the field, consistently yielding increases in efficacy which 
promise the goal of complete responses. The experiments presented in this work are such 
advancements. On the basis of the data presented, it can be concluded that: 
1) T cells have a differentiation mechanism via Fas that can act in a paracrine manner 
(Figures 4.1, 4.2, 4.3, Klebanoff et al., 2016). 
2) Fas has two distinct functions that can be distinguished by a C194V mutation- 
death and differentiation (Figure 4.1, Klebanoff et al., 2016). 
3) The Fas-mediated differentiation signal is dependent upon AKT and reciprocally, 
AKT inhibition prevents Fas- mediated differentiation (Figure 4.4) (Klebanoff et 
al., 2016). 
4) Fas-mediated differenitation attenuates T cell adoptive immunotherapy efficacy 
and Fas blockade augments efficacy of cultures with mixed differentiation (Figure 
4.5, Klebanoff et al., 2016). 
5) AKT inhibition prevents the differentiation of T cells transduced with a CD19 CAR 
(Figure 4.6, Klebanoff et al., 2017). 
6) AKT inhibition lowers the glycolytic activity of T cells transduced with a CD19 
CAR (Figure 4.6, Klebanoff et al., 2017). 
7) AKT inhibition promotes FOXO1 nuclear localization (Figure 4.8, Klebanoff et al., 
2017). 
8) FOXO1 expression maintains a T cell memory phenotype (Figure 4.9, Klebanoff et 
al., 2017). 
9) AKT inhibition of CAR-T cells yields superior tumor treatment efficacy. (Figure 
4.10, Klebanoff et al., 2017). 
 
Inhibition of AKT is being applied in clinical trials of adoptive immunotherapy and is used 
in the first FDA-approved commercial adoptive T cell immunotherapy in the United States. 
Furthermore, the marked control of differentiation is not exclusive to AKT inhibition; Fas 
may be targeted as well. Given Fas’ role in apoptosis however, care must be taken in an 
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approach which attenuates the death pathway, as cells could retain DNA damage or 
alterations that would normally prompt the Fas- dependent death pathway but are inhibited 
from doing so. In regards to FasL mediating T-cell differentiation, a FasL mimicking 
antibody or recombinant protein could be used which targets undifferentiated T cell 
malignancies in order to differentiate them. Also, to follow the path of investigation 
FOXO1 has illustrated, would cells with enforced FOXO1 activity treat tumor in 
concordance with the 62L expression it maintains on T cells? Such questions are well 
within the realm of practical investigation, and addressing them would further advance the 
field.   
 
In summary, by investigating facets of T cell proliferation and differentiation, novel and 
practical methods of culturing T cells for adoptive immunotherapy have been found. These 
insights can be translated to more effective applications of adaptive T-cell immunotherapy 
for the management of cancer patients. 
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7 METHODOLOGY 
 
7.1 Study Approval  
 
Animal experiments were conducted with the approval of the NCI and NIAMS Animal 
Use and Care Committees. All anonymous NIH Blood Bank donors and cancer patients 
providing human samples were enrolled in clinical trials approved by the NIH Clinical 
Center and NCI institutional review boards. Each patient signed an informed consent form 
and received a patient information form prior to participation. Reproduced with permission 
from the Journal of Clinical Investigation (Klebanoff et al., 2016). 
 
7.2 Cell Culture 
 
Tumor cell lines were maintained in R10 medium, which consisted of RPMI 1640 medium 
(Lonza) supplemented with 10% FBS (Hyclone), penicillin/streptomycin (100 U ml–1/100 
µG ml–1; Lonza), and 2 mM GlutaMAX (Invitrogen). T cells were maintained in T cell 
media, which consisted of AIMV (Invitrogen) supplemented with 5% human serum 
(Valley Biomedical), penicillin/streptomycin, nonessential amino acids (Gibco), 
GlutaMAX (Thermo Fisher Scientific), 0.055 mM 2-mercaptoethanol (Gibco), and 50 CU 
ml–1 of rhIL-2 (Novartis). Where indicated, cells were cultured continuously with 
indicated concentrations of AKTi (Calbiochem) dissolved in DMSO (MilliporeSigma). 
Reproduced with permission from the Journal of Clinical Investigation (Klebanoff et al., 
2016). 
 
7.3 Antibodies and Flow Cytometry 
 
Mouse cells were stained with fluorochrome-conjugated antibodies against combinations 
of the following surface and intracellular antigens after Fc receptor blockade (2.4G2): 
CD8α (clone 53-6.7), CD27 (clone LG.3A10), CD44 (clone IM7), CD45.1(clone A20), 
CD45.2 (clone 104), CD62L (clone MEL-14), CD90.1 (clone OX-7), CD90.2 (clone 53-
2.1), CD95 (clone Jo2), CD122 (clone TM–β1), CD178 (clone MFL3), IFN-γ (clone 
XMG1.2), KLRG-1 (clone 2F1), and Sca-1 (clone D7) (all purchased from BD 
Biosciences). Fluorochrome conjugates against pS6 S235/236 (D57.2.2E), pAKT T308 
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(C31E5E), and pAKT S473 (D9E) were obtained from Cell Signaling Technologies. 
Human cells were stained with combinations of the following fluorochrome-conjugated 
antibodies: CCR7 (150503), CD28 (CD28.2), CD45RO (UCHL1), CD8 (SK1) (BD 
Biosciences) or CD27 (M-T271), CD45RA (HI100), and CD62L (DREG-56) 
(BioLegend). Stimulation of T cells for intracellular cytokine staining was accomplished 
using Leukocyte Activation Cocktail containing phorbol myristate acetate and ionomycin 
in combination with brefeldin A and monensin solution (BD Biosciences). Apoptosis and 
specific cell death in defined T cell subsets was assessed using fluorochrome-conjugated 
annexin V and 7-AAD (both from BD Biosciences), as previously described (Abu Eid et 
al., 2015). Where indicated, TN-derived and TMem-derived subsets were reisolated for 
additional analyses by FACS sorting to greater than 92% purity using FACS sorting or 
magnetic bead isolation. Cell viability was determined using PI exclusion in FACS-sorting 
experiments or fixable live/dead cells (Invitrogen) for diagnostic experiments. For FACS–
based glucose uptake assays, we incubated CD8+ T cells with 100 µM 2-NBDG 
(Invitrogen) for 2 hours before measuring by FACS, as previously described (Chandran et 
al., 2015). Flow cytometric data were acquired using either BD FACSCanto II, LSR, or 
LSRFortessa cytometers (BD Biosciences). FACS data, including calculation of PI, were 
analyzed with FlowJo Version 9.7 software (TreeStar). Reproduced with permission from 
the Journal of Clinical Investigation (Klebanoff et al., 2016). 
 
7.4 Mouse Strains and Animal Studies  
 
Adult (6 to 12 weeks old) female C57BL/6 (B6; Ly5.2+), B6.SJL-Ptprca Pep3b/BoyJ 
(Ly5.1+), B6.PL-Thy1a/CyJ (Thy1.1+), B6.MRL-Faslpr/J (lpr) (44), B6.129S7-
Rag1tm1Mom/J (Rag), B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J (pmel-1) (24), and B6-
Tg(TcraTcrb)1100Mjb/J (OT-1) (Hedrick et al., 2012) CD8+ TCR transgenic mice were 
all purchased from the Jackson Laboratory. Transgenic mice harboring the Fas C194V 
mutant receptor were generated via BAC containing the Fas locus, with the C194V 
generated by recombineering. These mice were backcrossed to lpr mice on a B6 
background. FasC194V lpr/lpr mice were backcrossed to homozygosity for both the lpr 
Fas allele and the C194V Fas transgene. Where indicated, pmel-1 and OT-1 mice were 
crossed to Thy1.1, Ly5.1, Rag, or Rag × lpr backgrounds. All mice were maintained under 
specific pathogen–free conditions. Reproduced with permission from the Journal of 
Clinical Investigation (Klebanoff et al., 2016). 
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7.5 Mouse Xenograft ACT Studies  
 
Female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (The Jackson Laboratory) mice were used at 
≥ 6 weeks of age. Mice were inoculated by i.v. tail vein injection with 2 × 106 NALM6-
GL cells. Three days later, mice were randomly assigned to receive either no T cells or 1 × 
106 human anti-CD19 CAR–transduced T cells expanded in the presence or absence of 
AKTi administered by i.v injection. No exogenous cytokine support was administered 
following adoptive transfer. Tumor burden was evaluated using bioluminescent imaging 
with a Xenogen Spectrum system and Living Image v3.2 software following i.p. 
administration of 150 mg/kg of D-luciferin (Caliper Life Sciences). Reproduced with 
permission from JCI Insight (Klebanoff et al., 2017). 
 
7.6 Xenografted Cell lines  
 
The following CD19+ cell lines were used as positive controls: NALM6 (DSMZ), 
NALM6-GL (a previously described NALM6 line stably transduced with firefly 
luciferase) (Sabatino et al., 2016), and Toledo (ATCC). K562-CD19 (Kochenderfer et al., 
2009) and 143B-CD19 (Long et al., 2015) (a gift from C.L. Mackall, Stanford University, 
Stanford, California, USA) are both CD19– tumor cell lines stably transduced with CD19. 
The following CD19– cell lines were used as negative controls: K562 (ATCC) and CEM 
(ATCC). Reproduced with permission from JCI Insight (Klebanoff et al., 2017). 
 
7.7 Evaluation of vaccine-induced and antitumor immunity  
 
Adult female B6 mice were implanted by s.c. injection with 4 × 105 B16 (H-2Db) cells, a 
spontaneous gp100+ murine melanoma cell line obtained from the NCI tumor repository. 
Ten days later, tumor-bearing mice received 6 Gy total body irradiation. Treated mice 
received i.v. injection of indicated doses and subsets of pmel-1 CD8+ T cells in 
combination with 2 × 107 pfu of a previously described recombinant vaccinia virus (rVV-
gp100) (24) (rVV-gp100) and 12 µg IL-2 (Prometheus) administered twice daily by i.p. 
injection for a total of 6 doses. All tumor measurements were performed in a blinded 
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fashion. Reproduced with permission from the Journal of Clinical Investigation (Klebanoff 
et al., 2016). 
 
7.8 Isolation and Generation of Mouse and Human CD8+ T Cell 
Subsets 
 
Mouse TN cells were isolated either by using a MACS CD8+ negative selection kit 
(Miltenyi Biotech) in combination with a 1:300 dilution of biotin-conjugated anti-CD44 
antibody or by FACS sorting CD44loCD62LhiCD8+ T cells using FACSAria (BD 
Biosciences). Mouse TMem cells were generated by in vitro differentiation (as previously 
described) or by adoptive transfer of congenically distinguishable Thy1.1+ or Ly5.1+ 
pmel-1 CD8+ T cells into Ly5.2+ WT mice, where recipient mice were vaccinated with 
rVV-gp100 (2 × 107 PFU) and vaccine-induced TCM (CD44hiCD62L+) or TEM 
(CD44hiCD62L–) adoptively transferred subsets were isolated by FACs sorting more than 
28 days later (Macintyre et al., 2011, Sukumar et al., 2016). Human T cells were obtained 
either by leukapheresis or venipuncture and prepared over Ficoll-Hypaque gradient (LSM; 
ICN Biomedicals Inc.). Human TN cells and TMem cells were obtained by magnetic bead 
isolation using the EasySep Human Naive CD8+ T Cell and Memory CD8+ T Cell 
Enrichment Kits, respectively (STEMCELL Technologies). Fate tracking of TN and 
TMem cells was accomplished by labeling cells with Cell Proliferation Dye eFluor 450 
and Cell Proliferation Dye eFluor 670, respectively (eBioscience). Reproduced with 
permission from the Journal of Clinical Investigation (Klebanoff et al., 2016). 
 
7.9 Activation and expansion of CD8+ T cells 
 
Both mouse and human TN cells with or without TMem cells were activated and expanded 
at indicated ratios in 96-well round-bottom plates coated with 2 µg/ml of CD3-specific and 
1 µg/ml of soluble CD28-specific antibodies (clones 145-2C11 and 37.51; BD 
Biosciences) in culture media containing 5 ng/ml (mouse) or 20 ng/ml (human) of IL-2 at a 
final density of 1 × 105 cells/well. Where indicated, T cells were cultured with specified 
concentrations of lz-FasL, a previously described recombinant oligomerized form of FasL 
(Abu Eid et al., 2015), or 10 µg ml–1 of either a blocking antibody against FasL (MFL3; 
BD Biosciences) or IgG (A19-3; BioLegend). In some experiments, cells were also 
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cultured with 1 µM of AKT Inhibitor VIII (Calbiochem) dissolved in DMSO (Sigma-
Aldrich). Where indicated, TN-derived and TMem-derived subsets were reisolated for 
additional analyses by FACS sorting to more than 95% purity using FACS sorting or 
magnetic bead isolation. Reproduced with permission from the Journal of Clinical 
Investigation (Klebanoff et al., 2016). 
 
7.10 Isolation, Expansion, and Retroviral Transduction of Human T 
Cells with a Clinical-Grade CAR or TCR  
 
Generation of anti-CD19 CAR–transduced human T cells was accomplished using a 
previously described manufacturing process identical to that currently used for prior and 
current human clinical trials (Kochenderfer et al., 2015). Briefly, unfractionated PBMC 
were obtained either by leukapheresis or venipuncture from healthy donors (HDs) or 
patients and prepared over Ficoll-Hypaque gradient (ICN Biomedicals Inc.). Cells were 
resuspended in IL-2 containing media (300 IU ml–1), and T cell proliferation was initiated 
using 50 ng ml–1 of anti-CD3 antibody (OKT3; OrthoBiotech). Alternatively, FACS-
sorted T cell subsets were stimulated with anti-CD3/CD28 activator beads (Invitrogen) at 
1:3 T cell/bead ratio. RetroNectin (Takara Bio Inc.) was applied to nontissue culture–
coated 6-well plates using an established protocol (Johnson et al., 2009), followed by 
addition of a previously described MSCV-based splice-gagvector (MSGV) retrovirus 
encoding either the FMC63-28z CAR (Kochenderfer et al.,. 2009) or a HLA-A*02 
restricted NY-ESO-1 TCR (Robbins et al., 2008). Two days after T cell stimulation, 2 
×106 stimulated PBMC/well were added to retrovirus-coated plates and subsequently 
cultured overnight at 37oC. The next day, the cells were returned to culture in T cell 
media. Countbright beads were spiked-in for the flow cytometric quantification of relative 
and absolute cell numbers (Invitrogen). Reproduced with permission from JCI Insight 
(Klebanoff et al., 2017). 
 
7.11 Antigen-Specific Functional Assays of CAR-modified T Cells  
 
Specific IFNγ release by anti-CD19 CAR–modified T cells was measured by ELISA assay 
(Pierce) from supernatants following overnight coculture at a 1:1 ratio with indicated 
CD19+ and CD19– target cell lines in IL-2–free/AKTi-free culture media. Intracellular 
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cytokine staining (ICS) and tumor cell cytolysis was measured after a 6-hour coculture in a 
1:2 ratio of anti-CD19 CAR–modified T cells to indicated tumor cell lines. Tumor cell 
cytotoxicity by receptor-engineered T cells and calculation of the tumor-elimination index 
was performed as described elsewhere (Mastaglio et al., 2017). ICS was performed in the 
presence of 1 µl of Golgi Plug (BD Pharmingen). Cells were subsequently washed, stained 
for viability and cell surface markers, permeabilized according to the manufacturer’s 
instructions using a Cytofix/Cytoperm kit (BD Biosciences), and stained using 
fluorochrome conjugated antibodies against IFNγ (clone RPA-T8; BioLegend) and IL-2 
(clone MQ1-17H12; BD Biosciences). Evaluation of cytolysis by receptor-engineered T 
cells was performed as previously described (Mastaglio et al., 2017) and calculated as the 
antigen-specific tumor elimination index. Reproduced with permission from JCI Insight 
(Klebanoff et al., 2017). 
 
7.12 Antibodies and Flow Cytometry of Human CAR-T Cells.  
 
Cells were stained with fluorochrome-conjugated antibodies against combinations of the 
following surface antigens: CD3 (SK7), CD4 (RPA-T4), CD8 (SK1), and CD62L (DREG-
56) (all from BD Biosciences); CD28 (CD28.2, eBioscience); LAG-3 (17B4, Enzo); PD1 
(MIH-4, Invitrogen); and TIM-3 (344823, R&D Systems). Fluorochrome conjugates 
against phoshpo-S6 S235/236 (D57.2.2E), phospho-AKT T308 (C31E5E), and phospho-
AKT S473 (D9E) were obtained from Cell Signaling Technologies. Detection of the 
mouse anti–human CD19 scFv as a measure of transduction efficiency was detected as 
previously described (Kochenderfer et al., 2009). Briefly, Fc receptors were blocked with 
polyclonal goat IgG (Invitrogen), followed by incubation at 4oC for 25 minutes with 
biotin-labeled goat anti–mouse F(ab)2 antibody (Jackson ImmunoResearch). Cells were 
then blocked with polyclonal mouse IgG (Invitrogen) and then stained with PE-labeled 
streptavidin (BD Biosciences). Flow cytometric data was acquired using a either a BD 
FACSCanto II or LSRFortessa cytometer (BD Biosciences). FACS-sorting was performed 
on a FACSAria (BD Biosciences). FACS data was analyzed with FlowJo Version 9.8.5 
software (TreeStar Inc.). Reproduced with permission from JCI Insight (Klebanoff et al., 
2017). 
 
 
7.13 Cytokine Release Assays of Murine T Cells 
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We pulsed B6 splenocytes with indicated concentrations of hgp10025–33 peptide and 
incubated cells with TN-derived pmel-1 CD8+ T cells at a 1:1 ratio overnight at 37°C. 
Supernatants were analyzed for mouse IFN-γ by ELISA (R&D Systems). Reproduced with 
permission from the Journal of Clinical Investigation (Klebanoff et al., 2016).  
 
7.14 qPCR and Western Blot 
 
For qPCR analysis, CD8+ T cell subsets were FACS sorted directly into RNAprotect Cell 
Reagent, and RNA was extracted using the QiaShredders and RNeasy Mini Kits (all from 
QIAGEN). cDNA was synthesized using the High Capacity RNA-to-cDNA kit (Applied 
Biosystems), and qPCR was performed on an ABI 7500 Fast Instrument (Applied 
Biosystems). Gene expression was quantified using probes targeting Ccr7, Cd27, Gzmb, 
Il7ra, Klf2, Sell, Tbx21, Tcf7, Tfrc, and Prdm1 (Applied Biosystems). For Western blot 
analysis, CD8+ T cells were sorted into FCS and subsequently lysed in protease inhibitor 
containing RIPA buffer (Cell Signaling Technology). Protein was quantified using the Bio-
Rad protein assay. We separated 30 µg of total protein on a 4% to 12% SDS-PAGE gel 
followed by standard immunoblotting with antibodies to pAKTT308 (C31E5E; Cell 
Signaling Technology), GAPDH (AB2302; EMD Millipore), and horseradish peroxidase–
conjugated goat antibodies to mouse and rabbit IgG (sc-2005 and sc-2004; Santa Cruz 
Biotechnology Inc.). Blots were developed using chemiluminescence (Thermo Fisher 
Scientific) and acquired using the ChemiDoc system (Bio-Rad Laboratories). Reproduced 
with permission from JCI Insight (Klebanoff et al., 2017). 
 
7.15 Metabolic Profiling 
 
ECAR was measured at 37°C using a Seahorse XFe96 Analyzer (Seahorse Bioscience) in 
XF media (nonbuffered RPMI 1640 containing 25 mM glucose, 2 mM L-glutamine, and 1 
mM sodium pyruvate) under basal conditions as previously described (Sukumar et al., 
2013). For FACS-based glucose uptake assays, T cells were incubated with 100 µM 2-
NBDG (Invitrogen) for 2 hours before measuring by FACS, also as previously described 
(Sukumar et al., 2013). T cells exposed to AKTi were maintained continuously in the 
presence of the inhibitor, including during incubation with 2-NBDG and during FACS 
analysis. Quantification of individual metabolites was accomplished using a combination 
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of GC/MS and LC/MS/MS platforms on CAR-modified T cells from 3 independent donors 
(Metabolon). Reproduced with permission from JCI Insight (Klebanoff et al., 2017). 
 
7.16 Microarray Analysis of Human T Cells  
 
Gene expression levels were determined using Human Gene 1.0 ST arrays (Affymetrix) 
according to the manufacturer’s protocols. Total RNA (300 ng) was used as starting 
material for cRNA amplification using the WT Expression kit (Invitrogen) according the 
manufacturer’s protocol. cDNA was reverse transcribed, fragmented, labeled using the 
GeneChip WT Terminal Labeling kit (Affymetrix), and hybridized on the arrays for 18 
hours according to the manufacturer’s directions. Arrays were stained and washed in the 
Fluidics Station 400 (Affymetrix) and scanned (Affymetrix 7G). Arrays data were 
imported into Partek Genomic Suite using RMA normalization after background 
subtraction. The expression and sequencing data discussed in this manuscript are deposited 
in NCBI’s GEO database and is accessible through the GEO series accession number 
GSE98078. Reproduced with permission from JCI Insight (Klebanoff et al., 2017). 
 
7.17 Confocal Immunofluorescence Imaging and Analysis  
 
Fluorescence image z-stacks were collected using a 63× plan-apochromat (numerical 
aperture) oil immersion objective lens on a Zeiss LSM 880 laser scanning confocal 
microscope (Carl Zeiss Microscopy Inc.). Tiled images were acquired with 5% image 
overlap, an optical slice thickness of 0.9 um, 0.07 um x-y pixel size, and 0.44 um z-step 
size. The z-stack image tiles were stitched using the Zen blue (v2.3) software. The stitched 
images were analyzed using the ImarisCell image analysis software (v. 8.2.1, Bitplane 
Inc.), with the Hoechst counterstain used to mask the nuclear volume and the phalloidin 
stain used to mask the cytoplasmic volume. The same image processing and analysis 
parameters were used for each of the images within a dataset. The mean intensity of the 
respective fluorescence channels was measured within the nucleus and cytoplasm, and the 
ratio of cytoplasmic to nuclear mean intensity was calculated for the individual cells. The 
multichannel fluorescence confocal image z-stacks were analyzed using the ImarisCell 
volume reconstruction module of the Imaris software. Briefly, within the ImarisCell 
module, the “cell with single nucleus” criterion was used to segment the nuclear volume 
compared with the cell cytoplasmic volume. The Hoechst fluorescence channel was used 
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to segment the nucleus, whereas the phalloidin-Alexa Fluor 488 fluorescence channel was 
used to segment the cell cytoplasm. Segmentation was based primarily on intensity 
threshold for the respective channels above background. Background was calculated from 
the nonstained (no Hoechst and no phalloidin) negative control cells. From the 2 
segmented compartments within the individual cells, the FOXO1 mean pixel intensity was 
measured in an automated fashion for both the nucleus and cytoplasm. The same 
parameters used for segmenting the cellular compartments were applied to all cells in the 
dataset, regardless of treatment assignment. Reproduced with permission from JCI Insight 
(Klebanoff et al., 2017). 
 
7.18 Statistics  
 
The products of perpendicular tumor diameters were plotted as the mean ± SEM for each 
data point, and tumor treatment graphs were compared by using the Wilcoxon rank sum 
test and analysis of animal survival assessed using a log-rank test. Regression analysis of 
the slope of tumor regression as a function of CD62L+ cells among Fas-modulated CD8+ 
T cells was performed as described previously (Gubser et al., 2013). For all other 
experiments, data were compared using either an unpaired 2-tailed Student’s t test 
corrected for multiple comparisons by a Bonferroni adjustment or repeated measures 1-
way ANOVA, as indicated. In all cases, P values of less than 0.05 were considered 
significant. Statistics were calculated using Prism 5 GraphPad software (GraphPad 
Software Inc.) For microarray data, 1-way ANOVA was used to identify differentially 
expressed genes among the 4 T cell subtypes, with a significant cut off for the positive 
FDR < 0.01. Differentially expressed probe sets were selected without specifying a fold 
change criterion. Reproduced with permission from the Journal of Clinical Investigation 
(Klebanoff et al., 2016). 
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